[{"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner. They can be carried out with a smaller incision using minimally invasive surgery, but they are only suitable for people whose ligaments inside the knee are strong.\nMany more people facing surgery for knee problems would be better off with a partial rather than total knee replacement, which should allow them to recover faster, say experts.\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered. Those surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What risks are associated with getting either surgery? The story simply doesn\u2019t tell us.\nWhen considering harms, one needs to keep in mind the side effects of surgery, the recovery from surgery, how they function after recovery and then whether there are differences in the need for subsequent procedures.", "answer": 0}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nProfessor Vieta was not involved in this work, it is an independent comment.\n\"If we can confirm these results, then it's good news for people with Bipolar Disorder, as there is a great need for better treatments for the depressive phase of Bipolar Disorder\" said lead researcher Melanie Ashton of Deakin University in Australia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of NAC, according to Memorial Sloan Kettering Cancer Center, listed here,\u00a0are not mentioned.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is another example of a story about a screening test that didn\u2019t provide any information about the potential harms associated.\u00a0 While there are those who believe that the hs-CRP alone warrants drug treatment, this is not a universally held view.\u00a0 While the statins are relatively safe, they are not without potential side effects and are relatively expensive for the twenty plus years of potentially unnecessary treatment", "answer": 0}, {"article": "Whether you have surgery often depends on where you live and what doctor you see. Earlier studies show that a patient is 20 times more likely to have surgery in Idaho Falls, Missoula and Mason City, as compared to Newark, Bangor and Terre Haute.\nHe says his intent was not to put some orthopedic surgeons out of business.\nThe study was so controversial, Dr. Weinstein says, because \"I guess some of my colleagues were worried that I might find the wrong thing. I am not sure.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms of surgery are rare, the story should have mentioned\u00a0the possible complications such as wound infection or need for reoperation. The story also does not address potential harms of non-operative treatment, such as permanent nerve damage from cauda equina syndrome.", "answer": 0}, {"article": "Women whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent. The women whose cancers were detected by mammograms were less likely to be given chemotherapy.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted. \"The data from randomized trials and modeling show there is a very modest improvement in mortality with mammograms from 40 to 49,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss why mammography in younger women is not always beneficial and described several of the harms that the US Preventive Services Task Force discussed.", "answer": 1}, {"article": "\u201cI thought they had scanned the wrong person,\u201d said Dr. Smith, who is not related to the doctor in Massachusetts. \u201cI\u2019ve never seen anything like this.\u201d\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms. That could give Medicare grounds for denying payment when the drug is used off-label, as cancer drugs often are.\nProvenge from Dendreon, by contrast, trains the patient\u2019s immune system to attack the tumor. The drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated with XL184 even though information available from the company indicates that fatigue, diarrhea, nausea, high blood pressure, rash, \u2018hand-foot syndrome\u2019, and cough have been seen in the small cohort of men treated with XL 184 for 6 weeks or more.\nAnd while indicating that Provenge helped men with advanced prostate cancer live 4 months longer, there was no mention of any harms associated with use of this drug.", "answer": 0}, {"article": "The primary and secondary goals of the study are composites of several adverse outcomes. At the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cNo new safety problems cropped up in the 27,500 patient study.\u201d The\u00a0news release issued by the drug manufacturer Amgen about the same clinical trial revealed what was not known about potential harms for the use of the drug, as well as a number of contraindications, adverse events and harms that arose during the trial. The story would have done well to reference these.\u00a0", "answer": 0}, {"article": "The foregoing release contains forward-looking statements that can be identified by words such as \"could,\" \"potential,\" \"call for,\" \"accelerate,\" \"possible,\" \"suggests,\" \"expected,\" \"may,\" \"compelling,\" \"endorsement,\" \"potentially,\" \"growing,\" \"committed,\" or similar terms, or by express or implied discussions regarding potential new indications or labeling for Entresto, or regarding potential future revenues from Entresto. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Entresto will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Entresto will be commercially successful in the future. In particular, management's expectations regarding Entresto could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.\n\"This expert analysis adds to the already compelling case for the treatment of heart failure patients with reduced ejection fraction with Entresto,\" said Fabrice Chouraqui, president of Novartis Pharmaceuticals Corporation. \"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\nEntresto is a twice-a-day medicine that reduces the strain on the failing heart. It does this by enhancing the protective neurohormonal systems (Natriuretic Peptide system) while simultaneously inhibiting the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS).11 Other heart failure medicines only block the harmful effects of the overactive RAAS.12 Entresto contains the neprilysin inhibitor sacubitril, and the angiotensin receptor blocker (ARB) valsartan.11\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes extensive information on harms, including this summary of side effects: \u201cEntresto may cause serious side effects including serious allergic reactions causing swelling of the face, lips, tongue, and throat (angioedema) that may cause trouble breathing and death.\u201d", "answer": 1}, {"article": "The devices had been developed at EV3 Inc., a Plymouth med-tech company that Covidien acquired in 2010.\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes. It's a key finding, because patients with diabetes usually suffer from more advanced PAD and the blood vessels re-clog faster than for those who do not.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms from the approach.\nAny newly introduced device used in an interventional procedure has inherent risks both from the device itself and from the operator.\u00a0 The procedural complication rate is an important consideration especially since the new device is said to be as good as existing treatmemts.", "answer": 0}, {"article": "The authors of the new study wanted to look at what changes in diet do to one particular gut microbe species: a strain that\u2019s been associated with leanness and better glucose tolerance in mice. They wrangled a group of 49 overweight and obese adults, took stool and blood samples and asked them to follow a six-week calorie-restricted diet (between 1,500-1,800 calories per day) while increasing their fiber intake. The diet was followed by six weeks of eating normally. They kept a food journal throughout, and the researchers biopsied their fat tissue.\nThe good news is that your initial levels are not your fate. People who started out with lower stores of had more after they followed the fiber-rich calorie-restricted diet. You can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\nYou no longer live in a world where you can pretend you\u2019re only eating for one; the trillions of bacteria in your gut, we now know, also feed on what you put in your mouth\u2014and they behave very differently depending on what that is.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss risks associated with increasing your intake of dietary fiber. However, that\u2019s likely because there are few (if any) health risks associated with increasing fiber in your diet. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines. Founded in 1889, ESA today has nearly 7,000 members affiliated with educational institutions, health agencies, private industry, and government. Members are researchers, teachers, extension service personnel, administrators, marketing representatives, research technicians, consultants, students, and hobbyists. For more information, visit http://www. .\nThey found that the OFF! Clip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t give even a brief nod to harms. In addition to questions about the product\u2019s effectiveness, Consumer Reports pointed out that the active ingredient in the device is metofluthrin, a neurotoxin.\n\u201cThe label says, \u201cAvoid breathing vapor,\u201d but it\u2019s hard to imagine how, with the repellent swirling around you,\u201d according to Consumer Reports.\nThis seems to\u00a0be a critical oversight as the vapors will be inhaled by the people who are supposedly being protected as well as the mosquito.\nJohnson & Johnson\u2019s product website has a list of warnings buried under the topic, \u201cPrecautionary Statements.\u201d\n\u201cHAZARDS TO HUMANS AND DOMESTIC ANIMALS: CAUTION: Harmful if swallowed, inhaled, or absorbed through the skin. Avoid contacting skin, eyes, or clothing with treated refill cloth. Avoid breathing vapor. Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, or using tobacco. Remove and wash contaminated clothing before reuse. Store away from food, beverages and pet food. Do not use indoors or in enclosed spaces. Do not touch unit with metal instruments or wet hands. Do not allow materials of any kind to cover the unit while it is in use. Replace refill only when unit is off.\u201d ", "answer": 0}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer. While doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nEverybody agrees that CT \u201cdoes find the early stage lung cancer,\u201d said Dr. Heidi Roberts, a lung cancer researcher from Women\u2019s College Hospital, Toronto who wasn\u2019t involved in the new study. Early-stage cancer is easier to treat and has a higher survival rate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of what may have been observed in the study, but adequate general caveats were given:\n\u201c\u2026 each scan exposes a person to radiation, which also slightly increases cancer risks over time with repeated scans.\nAnd screening comes with an inherent risk of false-positives \u2014 scans which suggest a lung cancer that turns out not to be there.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer. While doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nAnd for some patients, \u201cif you really weren\u2019t going to benefit from the screening\u2026that complication is something you may not have faced,\u201d Berg said. \u201cThose are some of the things I worry about.\u201d", "answer": 1}, {"article": "Laxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood. Some drugs that treat the pain, including opiates, can make the constipation worse, he said.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\nAs many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health. The condition is poorly understood and somewhat vaguely defined, so estimates are not very precise. About one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Not everyone agreed with that notion, however.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no real \u201charms\u201d with using formula, either cow\u2019s milk formula or extensively hydrolyzed formula.\u00a0 It appears the latter may be a better choice because there are fewer proteins broken down for digestion.", "answer": 1}, {"article": "Eaton's part of the testing is finished. He says he's glad he took part, even though it hasn't quite turned him into an Olympic runner.\nThe reduction was up to 25 percent, while current therapies including medication and pacemakers typically reduce the size by only about 5 percent, he said. The reduction in swelling increases the heart's ability to pump blood, he said. By implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\nIn the study, stem cells were taken from the patient's own bone marrow and injected by catheter into scar tissue in the patient's heart caused by an earlier heart attack. It worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said. The hope was that the immature adult stem cells would turn into heart muscle, replacing the scar tissue.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, none of the participants experienced \u201csignificant side effects,\u201d but it would have been helpful to define what \u201csignificant\u201d means. For example, the study authors define serious side effects as death, non-fatal heart attack or stroke, hospitalization for worsening heart failure, blood flow compromise, or atrial fibrillation. While none of the subjects experienced these more serious side effects, the study did report that people had other issues such as premature ventricular complex, increased heart rhythm, and fluid buildup around the heart. Even when describing a study this small, the story should quantify the harms.\n", "answer": 0}, {"article": "Anthocyanin profiles among common processed forms of raspberries (frozen, juice concentrate, seeded puree, and seedless puree) on the U.S. market were investigated. Thirty-four samples - both domestic and imported - were reviewed. Seven individual anthocyanins were identified in the samples. While anthocyanin profiles varied slightly, contents varied considerably. This may reflect differences in varieties, origins, processing methods among other influential factors.\nWhile additional research, particularly in humans, is warranted, preliminary evidence from these studies suggests that the actions of essential nutrients, fiber, and polyphenolic phytochemicals found in red raspberries may play a role in supporting key metabolic functions, including anti-inflammatory, anti-oxidative and metabolic stabilizing activity. While this emerging research is promising, and contributes to the overall understanding of the health benefits of red raspberries, conclusions cannot be drawn at this time.\nDr. Giuliana Noratto and colleagues of the Department of Food and Nutrition Science at Texas A&M University studied if dietary supplementation with red raspberries could modulate the fecal microbiota of obese mice with diabetes and dyslipidemia. In this animal study, raspberry supplementation was associated with higher levels of Lachnospiraceae - a family of bacteria that can be depleted during diseases of the intestinal tract, such as inflammatory bowel disease. These findings provide a basis for formulating hypotheses for conducting additional studies, particularly in human trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release didn\u2019t mention any harms from eating raspberries, but that may be because there are no documented harms. Unless you are allergic, it seems safe to eat raspberries in moderation like any other fruit or vegetable.\nStill, out of eight studies it\u2019s reasonable to think one of them examined potential harms or made a statement about the lack of harms. Even noting \u201cthere were no observed harms\u201d would be helpful.", "answer": 2}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle. At issue are the surgical approaches that physicians use when a patient suffers from a hernia in the groin.\nWhy use the traditional approach if the laparoscopic technique is better in some ways? The traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nBrunt said the costs of the two procedures are comparable, although the laparoscopic procedure may cost more.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that the less invasive surgery might not be appropriate for patients who face increased risk from general anesthesia, including the elderly or those with multiple health problems. We\u2019ll rule this satisfactory, but the story could also have noted that the less invasive procedure produced a higher rate of operative complications than the standard procedure (6% vs. 2%).", "answer": 1}, {"article": "Genentech developed Lucentis to treat the wet form of age-related macular degeneration, the most common cause of severe vision loss in the elderly. While Avastin, which is a cancer drug, has not been approved for use in treating macular degeneration, it has the same mechanism of action as Lucentis. And Avastin costs only about $50 per injection into the eye, compared to roughly $2,000 for Lucentis.\n\u201cThe data is going to be interpreted many different ways,\u2019\u2019 said one investigator in the trial, who spoke under condition of anonymity but would not provide any trial results. Revealing trial results before they are published or presented at a conference is considered a violation of scientific protocol.\nIf this finding is considered valid, it could render the results of the National Eye Institute trial somewhat moot by raising safety questions about Avastin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms in the NEI trial couldn\u2019t be quantified, as results weren\u2019t available. That may\u2019ve been excusable if the story had acknowledged that more information \u2014 potentially extremely important \u2014 would be available upon publication. We give it credit for noting that the trial\u2019s size could only detect major differences in safety, but it doesn\u2019t discuss whether any such differences were observed or might be; are we to assume from their silence that the two informants blessed the safety? Given the 57% increase in hemorrhagic stroke risk mentioned from the Genentech trial, one would think a major difference is a live concern, and the outcome was worth mentioning even qualitatively for balance.\n\n \nThe relative risks of the Roche Genentech study are presented, as well as a number of grains of salt.\u00a0 We wish the Times had given a bit more information as journalist Jim Edwards, in his Placebo Effect blog, wrote:\n", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\n\"Our results were absolutely dramatic. It is tremendously exciting,\" Porter tells WebMD. \"These kinds of outcomes don't come around very often. We are really hopeful that we can now translate this into treatment for much larger numbers of patients and apply this technique to other diseases and to many more patients.\"\n\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD. \"These genetically engineered cells did what everyone in the field has tried to do for 20 years. The man probably had kilograms of disease in his body, and the cells mopped it up completely.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a three-person study, it\u2019s difficult to quantify harms or benefits beyond just describing what happened to each patient. The WebMD story, though, did a better job of presenting the very real side effects of the study, even showing that the treatments for the side effects may have hampered the effectiveness of the cancer therapy. \u201cThe treatment was not a walk in the park for patients. One of the three patients became so ill from the treatment that steroids were needed to relieve his symptoms. The steroid rescue may be why this patient had only a partial remission.\u201d", "answer": 1}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nFirst, he notes, the Hopkins team will need to demonstrate that the test will be useful in patients without symptoms. Then the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job of finding an independent source who explains that one of the potential risks of cancer screening tests is either identifying cancers that are not there, or are benign, and can lead to \u201cpointless and potentially dangerous treatments.\u201d\nThe opposite harm is also mentioned; that is, a screening test that erroneously gives a negative result, leading providers to falsely reassure a patient\u00a0that cancer is not there.", "answer": 1}, {"article": "[More women want big butts and the stats don't lie]\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart. That might seem like a lot of pain for the pleasure of a slimmed-down chin, but currently patients looking to part with their double chins must have fat removed through more invasive means, such as liposuction.\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face. The most common side effects included swelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection. FDA officials said Kybella should be administered only by a \"licensed health care professional,\" and shouldn't be injected anywhere other than below the chin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the FDA\u2019s warning that \u201cthe new drug can cause serious side effects, including trouble swallowing or\u00a0nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\u201d It then lists side effects, which\u00a0included \u201cswelling, bruising, pain, numbness, redness and areas of hardness in the vicinity of the injection.\u201d\nThis is sufficient for a Satisfactory rating. But the story could have could have mentioned a key concern cited by the FDA in the second sentence of its news release: \u201cUsing Kybella for the treatment of fat outside of the submental area is not approved and is not recommended.\u201d A reworded version of that warning is repeated twice more in the news release.", "answer": 1}, {"article": "The devices were used to quickly vaccinate large numbers of people, including members of the armed forces.\nNow, Gomaa's lab is looking beyond the flu vaccine. She says the microneedle patch could be particularly helpful in developing countries because it uses a form of vaccines that doesn't need to be kept as cold as regular vaccines. It can be stored at temperatures as high as 104 degrees Fahrenheit for up to a year, she says.\nAnd the patch can be administered by people who aren't trained health professionals. A number of the people in the flu patch study applied it to themselves.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the article headline is convenience and comfort. It follows through on that focus by doing a fairly good job of addressing side effects of the various delivery mechanisms, though again, the information is somewhat uneven. The most thorough description of harms is provided in the flu patch section of the story, where we learn that participants in the clinical trial had\u00a0some redness, itching and tenderness but no serious side effects. About the jet injection we learn it is much less painful than when it was used for smallpox vaccination back in the 1960s. The story also informs us that nozzles are changed between patients so the former problem with infection from using the same equipment has been resolved. No other harms (like the redness and itching associated with the patch, for example) are mentioned. The section of the story on nasal spray vaccines is short, and it doesn\u2019t include any information about side effects or harms.", "answer": 1}, {"article": "\"It's typically performed with a local anesthetic and sedation. It takes an hour or less,\" he said. \"Most patients return home the same day.\"\nIn contrast, the risk of failure among recently recalled defibrillators has been estimated by the manufacturers at just 0.009 percent to 2.6 percent. And not every failure is deadly.\nThe researchers studied 2,915 patients who were tracked by 17 Canadian hospitals in 2004-05. All the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article lists all harms noted in the study, both serious and less serious, and explains that the authors did not track what happened to patients who did not have devices replaced. The story did note that untreated abnormal rhythms can be \u2018potentially deadly\u2019. However, the article notes that manufacturers estimate the rate of failure for devices that are subject to safety advisories, and also lists both the minor and serious things that can go wrong with them. One big issue that is not dealt with well is that the initial decision threshold for putting these devices in place may change now, based on the higher failure rates and the higher rates of complications with replacement.", "answer": 1}, {"article": "SpermCheck Fertility is designed to help couples determine more quickly whether male infertility might be a problem for them, said Ray Lopez, CEO of SpermCheck, based in Charlottesville, Va. Many men put off having a semen analysis because they don't want to provide a sample in a doctor's office or lab, he said.\nMen tend to think they're perfectly healthy, especially when it comes to their sexuality, APA's Imler said. This test, which is noninvasive, could be wake-up call for some.\nPlaced among dozens of pregnancy, ovulation and female fertility kits, an at-home sperm test that hit retail shelves in April could help change that mentality, experts said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out that the test might lull men into a false sense that they have no fertility problems. \u201cA positive result from the SpermCheck Fertility test could give men a false sense that everything is all right, APA\u2019s Imler said.\u00a0It might even cause some men to delay a necessary doctor\u2019s evaluation, Brannigan said.\u201d\nThe story waited a little too long to make this point, but we were glad to see it included.", "answer": 1}, {"article": "Oxidative stress refers to a situation where levels of reactive oxygen species or \u201cfree radicals\u201d \u2014 damaging byproducts of energy use in cells \u2014 rise beyond the body\u2019s capacity to neutralize them. Long-term oxidative stress is believed to contribute to a host of chronic diseases.\nThere are caveats. The yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\nThe study, of 123 middle-aged and older adults, found that those who added yoga classes to standard diabetes care shed a handful of pounds over three months. Meanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This does not actually address what is known about any potential harms of the type of yoga reported on. \u00a0The story could have mentioned that the study mentioned that there were no adverse events reported during the 3 months of yoga classes but that about 5% of those assigned to the yoga classes dropped out and were not included in the final analysis.", "answer": 0}, {"article": "Invented 16 years ago by a radiologist who got the idea while playing video games on a flight simulator during advanced training at Johns Hopkins, virtual colonoscopy has become an increasingly popular alternative to standard, or optical, colonoscopy, which is typically performed by a gastroenterologist. Initially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nWhen Eric Rowe turned 50, the question was not whether the Washington lawyer would be screened for colon cancer, but how. His wife had undergone a colonoscopy, the gold-standard exam that costs about $1,500, but Rowe's internist recommended an alternative that was less invasive and expensive: a virtual colonoscopy, which uses three-dimensional images from a CT scan to detect benign polyps or cancers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the potential harms of the procedure, including radiation exposure (250 times that of a chest x-ray), missing small or flat polyps, and incidental findings that might lead to unnecessary treatments. The story could have also emphasized that about 20% will require a follow-up colonoscopy because of suspicious findings.", "answer": 1}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\n\u201cWe worried a lot that chemotherapy could be immunosuppressive,\u201d Wolchok said, noting that that might explain why the average survival benefit was two months instead of four.\nISI Group analyst Mark Schoenebaum said although the vemurafenib results look the most encouraging, the findings are unlikely to make a difference for current sales estimates, since virtually all eligible patients will be treated with both drugs, either in sequence or in combination.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned only skin rashes and joint pain from vemurafenib, but the story didn\u2019t explain, as the New York Times did, that 38% of trial participants had to stop taking the drug or lower the dose because of side effects. And there wasn\u2019t a word about side effects from ipilimumab.", "answer": 0}, {"article": "Analogous blood injections, in which the patient\u2019s own blood is taken and then injected into a specific area of the body, is used to help harness the healing power of blood to treat the degeneration of tendons. Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\nThe findings were published in The American Journal of Sports Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no attempt to quantify harms here. After reading this story, one might assume that there\u2019s nothing risky about this procedure.", "answer": 0}, {"article": "Breast cancer is a frequently diagnosed cancer and a leading cause of death in women. Diet has been extensively studied as a modifiable risk factor in the development of breast cancer but epidemiologic evidence on the effect of specific dietary factors is inconsistent.\nEditor's Note: Authors made conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer. Preventive strategies represent the most sensible approach against cancer. The intervention paradigm implemented in the PREDIMED trial provides a useful scenario for breast cancer prevention because it is conducted in primary health care centers and also offers beneficial effects on a wide variety of health outcomes. Nevertheless, these results need confirmation by long-term studies with a higher number of incident cases,\" the authors conclude.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Consuming both nuts and olive oil have been shown in numerous studies to be a positive asset to the regular diet. \u00a0And yet these foods are very calorie-dense, and so one wonders if consuming so much of them could increase the risk for weight gain, which is in turn associated with breast cancer risk. But the release\u2019s lack of discussion on that point shouldn\u2019t be enough for a Not Satisfactory rating \u2014 we\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\n\"I just loved it,\" his mother, Salma Shabaik, a family physician who lives in Los Angeles, says. \"It was really nice to have the baby right there beneath my eyes where I could feel him, touch him, kiss him.\"\nThis was a \"serendipitous magical finding,\" says Gray, suggesting that skin-to-skin contact acted something like a \"natural incubator.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention.", "answer": 1}, {"article": "About 57 million Americans have prediabetes, a disorder marked by blood sugar levels that are elevated but not sufficiently high to be considered diabetic. Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does not mention any harms associated with CPAP, that is likely because there are no significant health risks associated with the use of CPAP devices. However, it would have been worth noting that CPAP devices can often cause significant discomfort for users (and their bedmates), particularly at first. Getting CPAP to work can also require a lot of tinkering with the device.", "answer": 1}, {"article": "For more information go to GetAwair.com.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nSince most people spend about 90 percent of their time inside, having poor indoor air quality could affect your health and the health of your family members\u2014especially during winter.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concern here is that the story discusses a series of potential circumstances, many of which are either unlikely to harm human health or would only be potentially harmful to some people. For example, dry air is not a health concern for many people. This creates a potential \u201coverdiagnosis\u201d problem. In other words, using a product like Awair could potentially lead people to be concerned about circumstances that don\u2019t actually threaten their health. This may result in unnecessary worry, stress or anxiety, or in causing people to spend money on treatments or technologies \u2014 such as humidifiers or air filtration system \u2014 that they don\u2019t need. To be clear, there is a very real market for technologies like humidifiers and air filtration systems, but not everyone needs them. The story doesn\u2019t address these issues at all. Also, potential harm could come from false positives in the tracking device, but that isn\u2019t addressed, either.", "answer": 0}, {"article": "The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 7,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors. Despite these limitations, their experience suggests that complications of the DTI approach in older women are similar to those of the more commonly used TEI technique. Dr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nBoth DTI and TEI were safe and effective options for breast reconstruction. Complication rates were similar between groups, including blood and fluid collections (hematoma and seroma), infection, unplanned surgery, and failed reconstruction.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "In framing this emerging technique as \u201csafe and effective,\u201d as well as highlighting complication rates that are no different from the standard approach, this news release may be minimizing the very real complication rates. The release states, \u201cComplication rates were similar between groups, including blood and fluid collections (hematoma and seroma), infection, unplanned surgery, and failed reconstruction.\u201d\nThe rates may not have been any different between the groups but that does not mean harms can be dismissed. It\u2019s not hard to find disquieting statistics on the rate of complications after mastectomy with reconstruction, for instance this study showing a 10.3% overall complication rate after mastectomy with implant \u2014 and 6% of implants being removed within 60 days.\nThe published study mentioned previous research had found greater complication rates with the direct-to-implant approach. These contradictory findings are not mentioned in the news release.", "answer": 0}, {"article": "In a randomized clinical trial, more than 700 patients with coronary heart disease were split into two groups: half received four text messages per week for six months plus usual care, while the other half received just usual care.\nBut texting, that old-school technology, may deserve some of that spotlight, too.\n\"I like to look for things that are able to be used in multiple corners of our world, from low-income settings to high-income settings,\" Chow says. \"Everybody owns a mobile phone these days. You don't have to have a smartphone to text.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As long as people aren\u2019t driving and checking their cell phones, there don\u2019t appear to be any harms associated with receiving well-meaning text messages four times a week, so we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "After analyzing everyone\u2019s sleep waves, the team found that people\u2019s slow-wave oscillations increased on the nights punctuated by pink noise. Come morning, people who had listened to it performed three times better on memory tests than they had the other night. On the nights without the noise, memory recall did not improve as much.\nThat doesn\u2019t mean there aren\u2019t benefits to other soothing background sounds. Music, nature sounds and white (or pink) noise apps may still help improve sleep, she says\u2014which, in itself, is good for the body and for the brain.\nNorthwestern has a patent pending on the new technology, and one of the study authors has cofounded a company that plans to market it commercially. But first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night. The researchers hope to develop an affordable device that people can use at home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention harms at all. There may be no real harm to hearing these sounds as one sleeps, but we\u2019d like to see that question addressed.", "answer": 0}, {"article": "About Carolinas HealthCare System Carolinas HealthCare System (carolinashealthcare.org), one of the nation's leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs throughout North and South Carolina. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Carolinas HealthCare System works to enhance the overall health and wellbeing of its communities through high quality patient care, education and research programs, and numerous collaborative partnerships and initiatives.\nDrs. Asher and Burri emphasize that the real importance of this study is its potential to make us think differently about what really matters in cancer therapy.\nNewswise \u2014 CHARLOTTE, N.C., July 26, 2016 /PRNewswire-USNewswire/ -- Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical Association (JAMA). The study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy. These results will allow tens of thousands of patients with brain tumors to experience a better quality of life while maintaining the same length of life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The main point of the release, emphasized in several statements, is that whole brain radiation is more toxic to the brain than focused (or stereotactic radiation) without improving survival outcomes. So, while one might expect that the more targeted approach might cause harm by \u201cmissing\u201d some of the cancer, the story does a good job of pointing out the\u00a0LACK of additional harm by targeting the tumor rather than irradiating the entire brain.", "answer": 1}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We get some valuable description of how other oral medications have come into question (even after FDA\u00a0approval) because of side effects, and this context allows the reader to judge that perhaps it is too soon to see the new drug \u2013 Gilenya \u2013 as a complete home run. Side effects mentioned for Gilenya include liver toxicity, infection risk and eye problems.\n\u00a0", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The original AP story mentions that the vaccine may not be very effective and may be considered overtreatment in otherwise healthy younger smokers.\u00a0 But the NY Daily News cut out that part in what it published.\u00a0 Neither version mentioned potential side effects of the vaccine, which might include pain if adminstered via the muscle, and allergic reaction, though this is rare. ", "answer": 0}, {"article": "Cluster headaches are rare but devastating to their sufferers. Like migraines, they cause intense pain and an inability to function much at all when they strike.\nA study in the journal Headache last September showed the treatment appeared to help just over a quarter of cluster headache patients who tried it, versus about 15 percent of those given a sham treatment. This went up to about a third of patients with so-called episodic cluster headaches.\nThere aren\u2019t many specific treatments but they include the migraine drug sumatriptan, delivered via auto-injector, and inhaled oxygen. Both approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects were considered to be temporary and relatively minor, but should have been mentioned.\nDr. Silberstein noted, \u201cIt does not have the side effects or dose limitations of commonly prescribed treatments\u2026\u201d \u00a0This is perhaps true but a closer examination of the research results reveals that 11 percent of the participants treated with the gammaCore device saw lip or facial dropping/pulling or twitching during the sham controlled trial and 7 percent experienced these side effects during the open label part of the trial (when both the researchers and volunteers knew which treatment was being administered). ", "answer": 0}, {"article": "Experts have known for some time that taking folic acid can prevent neural tube birth defects like spina bifida in developing fetuses. American Congress of Obstetricians and Gynecologists (ACOG) guidelines call for all women of child-bearing age - not just those who plan to get pregnant - to take 400 micrograms of folic acid daily to prevent birth defects. The same dose appears to provide some benefit in preventing autism, according to the research.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are hypothetical, but plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story should have mentioned this.", "answer": 0}, {"article": "Knee braces basically help realign the knee; taking pressure off of damaged areas to relieve pain and restore function. Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nAll study participants led active lifestyles before they got sidelined by knee OA, and said they hoped to return to their previous level of activities. And by and large, they did. Their quality of life improved, and their activity level went from one that did not permit recreational sports to one that did.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing. The study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms that might be associated with the use of the devices reported on. \u00a0Are there any short term or potentially longer term implications resulting from the use of a knee brace?", "answer": 0}, {"article": "Vitamin D can be obtained in the diet, particularly from fortified foods, from supplements, and from sun exposure. Experts recommend vitamin D be obtained through diet whenever possible because excessive ultraviolet radiation is a major risk factor for skin cancer.\nA new study authored by scientists from the American Cancer Society, the Harvard T.H. Chan School of Public Health, the U.S. National Cancer Institute, and more than 20 other medical centers and organizations finds that higher circulating vitamin D concentrations are significantly associated with lower colorectal cancer risk. This study strengthens the evidence, previously considered inconclusive, for a protective relationship. Optimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health. The study appears online in the Journal of the National Cancer Institute.\n\"Currently, health agencies do not recommend vitamin D for the prevention of colorectal cancer,\" said Marji L. McCullough, ScD, American Cancer Society epidemiologist and co-first author of the study. \"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release indicates that vitamin D should ideally be obtained from the diet, and that there are no known harms to eating foods with vitamin D (an exception being when a mishap caused over-fortification of a local milk supply a few decades ago). Skin cancer risk associated with sun exposure was covered appropriately.", "answer": 1}, {"article": "\"He's actually getting his muscle to work,\" says Bishop. \"It's a perfect exercise.\"\nA study by researchers at the Nicholas Institute of Sports Medicine and Athletic Trauma, Lenox Hill Hospital in New York demonstrated this benefit. They found that adding the eccentric wrist extension exercises using the FlexBar was effective at improving strength and decreasing pain in patients with tennis elbow. (Performance Health Brands, maker of Thera-Band, provided the FlexBars for the study but did not fund it.)\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms. He says weights can overwork the muscle and sometimes leads to more pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FlexBar is probably safer than some other commonly used treatments for elbow pain such as steroid injections. However, the story doesn\u2019t really address safety, except to say that\u00a0traditional hand weights can sometimes make tennis elbow pain worse (and by implication, that the FlexBar won\u2019t). While this isn\u2019t a major concern of ours, we think\u00a0it\u2019s probably premature, based on a single 21-person\u00a0study,\u00a0to suggest that the FlexBar is safer than other noninvasive approaches to treating tennis elbow.", "answer": 0}, {"article": "Alzheimer\u2019s disease, the most common form of dementia, can be fully cured with an anti-inflammatory drug commonly used for period pain, a new research by the University of Manchester shows. Currently, no drug medications can successfully treat chronic neurodegenerative disease, but certain medicines can help alleviate symptoms or slow down the progression.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse. Our research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story does\u00a0allude to\u00a0harms, there are two problems. First, we are troubled that the explanation\u00a0was actually taken directly from the news release about the study. Second, we feel that it was too vague and not explored in any meaningful way. The story says only,\u00a0\u201cthey also warned that these \u2018drugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage\u2013studies in people are needed first.'\u201d What are the side effects? We\u2019re not told.", "answer": 0}, {"article": "Certain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\nBut the majority of those studies have focused on adults, and it\u2019s becoming clear that many of cancer\u2019s drivers start early in life, with genes and even with childhood exposures to potential carcinogens.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no significant risks with eating three servings of fruit per day during adolescence, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine. Both drugs have been used for impulsive conditions, including ADHD.\n\"The drug improves self-control, which is a key factor in determining obesity, so our hypothesis is that this drug should help in treating the disease.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nowhere in the release is there any mention of possible harms from taking Modafinil, although a brief web search suggest there are numerous potential side effects associated with the drug including anxiety, backache, sleeping problems and potential heart complications.", "answer": 0}, {"article": "\"It's kind of an extreme makeover of a cell,\" said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research. \"The goal is to create cells that are missing or defective in people. It's very exciting.\"\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms that might be associated with gene therapy even though there have been human deaths resulting from the use of viral vectors to alter gene expression.", "answer": 0}, {"article": "\u201cThe findings of our studies, along with clinical findings reported by other groups, indicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases,\u201d Sahebkar said.\nSahebkar said turmeric contains very low quantities of curcumin, usually less than 5 percent, and curcumin has a very low absorption in its raw form, usually less than one percent of raw curcumin is absorbed when taken orally.\nSahebkar said most of the clinical benefits reported for curcumin have been achieved when curcumin was added to a standard drug therapy regimen, and patients should be careful not to replace their prescribed drugs with curcumin without prior consultation with their physician.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that pregnant and lactating women should avoid using curcumin supplements, and quotes one of the study authors as saying that \u201cpatients with malabsorption syndrome, gall bladder problems, gastric ulcer, bleeding problems as well as those who are undergoing surgery, and those who have a history of hypersensitivity to herbal products should be cautious and consult with their physician before taking this supplement.\u201d\nWe\u2019ll rate this good enough for a satisfactory, although the story could have noted that many of these warnings seem to relate to the fact curcumin may interfere with iron metabolism (posing problems for those with iron deficiencies), and that curcumin can apparently also cause nausea, dizziness, or diarrhea in some people.", "answer": 1}, {"article": "The researchers looked at 19 studies on how a treatment, either hormones or soy, compared to a placebo. They compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study. Women with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nWomen who took such hormones had fewer hot flashes, on average, than women who took soy - and both had fewer than those who took a placebo, or \u201cdummy pill.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate job reminding readers of the risks reported from the 2002 Women\u2019s Health Inititiative study (although we wish it had given the absolute risk data).\u00a0 And it cited what the NIH reports as side effects of soy supplements \u2013 but again without numbers.\u00a0 Adequate nonetheless.", "answer": 1}, {"article": " Gilbert explained: \"With the swine flu pandemic it took four months before the first doses of the vaccine were available and there was only a small amount available,\" Gilbert explained. \"It took a further six months before it was possible to vaccinate a large number of people.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nLondon, England (CNN) -- Researchers hope a new treatment developed in the United Kingdom will prove vital in controlling future flu pandemics such as H1N1 (swine) flu, bird flu as well as ending the need for annual flu jabs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the frustration of having a diagnosis with no known treatments. However, when it comes to the intervention specifically\u2013the PET scan\u2013there are the risks of false-positives and false-negatives. As in, what\u2019s the risk someone is diagnosed when they don\u2019t have the disease, or they\u2019re not diagnosed when they do indeed have the disease? Every screening test has these risks\u2013it\u2019s important to know how likely they are.\nAnd, PET scans themselves expose people to radiation and can cause allergic reactions to the tracer.", "answer": 0}, {"article": "Cancer vaccines of the type represented by Provenge, known as immunotherapy, are different from conventional vaccines in that they do not aim to prevent disease, but to enlist the body\u2019s defenses in attacking the disease after it occurs. The cervical cancer vaccine now in use, Gardasil, is a more traditional preventive vaccine that works because cervical cancer is caused by a virus.\nStill, some members of the committee said the evidence was somewhat weak because that trial involved only 127 men. And it had been intended to measure something different \u2014 not whether Provenge prolonged life, but whether it delayed the worsening of cancer. And the drug failed to do that by a statistically significant measure.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests the drug\u2019s side effects are milder than those of standard chemotherapy. But the source of this assessment is a member of the study team who is a consultant to the drug maker. \nThere is no description from an independent source of the drug\u2019s safety profile.\u00a0 ", "answer": 0}, {"article": "A small study claims children with autism may benefit from fecal transplants, which involves introducing donated microbes into people with gastrointestinal disease to rebalance the gut. The Ohio State University, Northern Arizona University and Arizona State University researchers found a parallel between behavioral symptoms of autism and gastrointestinal distress, and improvements to both after fecal transplant.\n\u201cTransplants are working for people with other gastrointestinal problems,\u201d lead study author Ann Gregory, a microbiology graduate student at The Ohio state University, said in a news release. \u201cAnd, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable.\nThe study, which was published in the journal Microbiome, included 18 children with autism and moderate to severe gastrointestinal problems. The children ranged from 7 to 16 years old. A questionnaire was used to assess social skills, irritability, hyperactivity and communication. Parents and doctors reported improvements that lasted at least eight weeks after treatment. Children without autism were used as a control for the study, the news release reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are risks to introducing a donor\u2019s stool into a recipient. No mention of risk was included. A donor could have undetected disease or infection before donating.", "answer": 0}, {"article": "Cocaine use is widespread in the Western World. Last year, 2.3 million young Europeans (aged 15 to 34) used cocaine, and the US National Institute on Drug Abuse estimates that 1.4 million Americans suffer from cocaine addiction1. There is no effective drug treatment for cocaine addiction, with behavioural therapies being the main element of any treatment regime. Now a group of researchers working in Italy and the USA have shown in a preliminary clinical study that cocaine use can be reduced by treatment with rTMS (repetitive Transcranial Magnetic Stimulation).\nDr Bonci said: \"rTMS is a non-invasive and very safe therapeutic approach which is used with other mental health and neurological conditions, such as depression and neuropathic pain. Our study suggests that rTMS may also represent a new treatment for patients with cocaine use disorder\".\n\"This study represents a creative approach to a disorder that is notoriously difficult to treat in the real world. These pilot data also show that biological treatments nowadays reach far beyond medications and that new neuroscience methods may be used for targeted changes in brain regions relevant for complex mental disorders\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that the magnetic stimulation treatment is safe and non-invasive and is already in use to treat patients with depression and neuropathic pain.", "answer": 1}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any story that discusses the potential benefits of alcohol consumption should say a word or two about the potential harms of overdoing it, since heavier drinking is unequivocally related to a host of health risks. This story didn\u2019t\u00a0include any such warning.", "answer": 0}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions harms of hormone therapy, such as an increased risk of blood clots and uterine cancers. Notes that there were \u201cfewer side effects\u201d (i.e. blood clots and uterine cancers) in the raloxifene group, but does not mention that the difference in side effects was not statistically significant for uterine cancer and blood clots. This information was not readily available on the National Cancer Institute (NCI) website or in reports of the study, but we give this a \u201csatisfactory\u201d score because the story presents caveats on the drugs. Mentions reduction in the risk of cataracts with raloxifene, which was statistically significant. Does mention that raloxifene, like tamoxifen, has bothersome side effects such as hot flashes and vaginal discharge, which are reported as comparable and mild to moderate in the NCI press release of the initial results of this trial. ", "answer": 1}, {"article": "Hypertension - or high blood pressure - is a common obesity-related condition that affects about 30 percent of U.S. adults and it is a major risk factor for cardiovascular disease. Before age 50, an elevated diastolic blood pressure is associated with increased cardiovascular disease risk. As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\nEditor's Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of any harms arising from a diet rich in whole grains but we won\u2019t fault them from that. The benefits of whole grain foods have been well documented.\nProviding more detail on what the diets contained would have been helpful to readers.", "answer": 2}, {"article": "For more information on trauma, visit the U.S. National Institute of General Medical Science.\nLevy however, cautioned that the results of this study apply only to TXA and do not mean that people should try similar drugs hoping for similar results.\nCurrently, TXA is not generally used in emergency rooms to treat trauma patients, but Roberts believes that this study could change that.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story correctly\u00a0states that the researchers observed no increase in clots in the patients receiving TXA, earning enough for a satisfactory. However, we wish it had included, as the AP did,\u00a0a caveat regarding the difficulty of identifying clots\u00a0in\u00a0trauma patients who subsequently die.", "answer": 1}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Does not mention the increase in \ncholesterol and cardiovascular disease among the women in the aromatase inhibitor group. Tamoxifen may have a positive, \ncholesterol-lowering effect, which is also not mentioned. ", "answer": 0}, {"article": "WINSTON-SALEM, N.C. - Aug. 17, 2015 - Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury. Even if an injury does not occur, the fear of falling can lead to reduced activity and a loss of independence.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people. In addition, people in the vitamin D group reported approximately half the falls of those in the control group.\nThe Wake Forest Baptist team currently is conducting a clinical trial to try to determine how vitamin D affects risk factors for falls such as balance and muscle strength and power.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of possible harms caused by Vitamin D supplements, though the\u00a0FDA website cites a laundry list of concerns that it attributes to the American Association of Family Physicians: Nausea, vomiting, poor appetite, constipation, weakness, weight loss, confusion, heart rhythm problems, deposits of calcium and phosphate in soft tissues.", "answer": 0}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nDr. Wulf H. Utian, medical director of the North American Menopause Society, agrees that many reasons may underlie the lack of treatment. \u201cIt is partly \u2018fall out\u2019 from the controversy over hormone therapy,\u201d he told Reuters Health in an email.\n\u201cExtrapolating our findings to 3.7 million Australian women aged 40 to 64 years, we found that 455,000 women are likely to have moderate to severe vasomotor symptoms, with most women (385,000) remaining untreated,\u201d they write.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states several times that alternative therapies for menopausal symptoms, including vaginally applied estrogen, are safe. But elsewhere it acknowledges that pill-based treatment with hormones is associated with increased cancer risk. It would have been reassuring to provide some evidence backing up the claim that these alternative treatments are, in fact, safe \u2014 since that seems to be a key reason why women are reluctant to use these therapies. And certainly some of the nonhormonal options for hot flashes (e.g. antidepressant medication) carry a risk for side effects that could have been mentioned.", "answer": 0}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nDoctors use brain imaging, evaluation of behavior, psychiatric tests, and other means to diagnose the disease. None are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nThe only definitive way to diagnose the disease is by direct examination of brain tissue after the patient dies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not discuss the potential harms of this sort of test. As mentioned above, some healthy people would be told in error that they have signs of Alzheimer\u2019s Disease. Such a misdiagnosis could have profoundly grave consequences.", "answer": 0}, {"article": "In 2014, a study in Molecular Medicine showed that administering low doses of a thyroid hormone to rats with diabetes helped restore hormone levels in their hearts and prevented deterioration of heart function, adverse gene changes, and pathology. Earlier, a study in the Journal of Cardiac Failure found that thyroid hormone replacement therapy in rats significantly reduced the incidence of atrial fibrillation. A 2013 study in The Journal of Translational Medicine showed thyroid hormone treatment administered to rats at the time of a heart attack led to a significant reduction in the loss of heart muscle cells and improvement in heart function.\n\"What we have tried to do here is show the effect of safe doses of thyroid hormones and we're seeing amazing results in multiple studies, with dramatic improvements in heart function, gene expression, and collagen levels, just by restoring depressed thyroid levels in the heart,\" said Gerdes. \"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials. The experts once warned that Beta blockers were too dangerous to use in heart failure patients. But, they were proven to be wrong and these life-saving drugs are now standard therapy for heart failure treatment. I predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients. We are simply talking about restoring normal thyroid hormone balance in heart disease, not over-stimulating the heart.\"\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes. \"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension. The rats experienced overall improvement in contractile proteins and heart function too.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not adequately discuss potential harms. Thyroid hormone treatment for other conditions, such as hypothyroidism, has been around for years. And, in those cases, it\u2019s known that such treatment can cause side effects such as heart palpitations and insomnia. But there are other risks as well, which the release itself points out in a very roundabout way. The release says that the study\u2019s lead author \u201chas long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\u201d This sentence manages to highlight that there can be significant risks associated with the use of thyroid hormones (the \u201ctoxic doses\u201d reference), but it isn\u2019t clear what these risks are, and it\u2019s not made clear that there may be risks (even lesser risks) associated with the undefined \u201clow-dose\u201d applications of thyroid hormone used in this study.", "answer": 0}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle. More than 90 percent of cases are diagnosed in people older than 50, according to the National Cancer Institute.\nAspirin and NSAIDs carry their own risks, however. Long-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is straightforward in saying that all NSAIDs carry risks.\n\u201cLong-term use can cause gastrointestinal bleeding, for example, so the potential reduction in colon cancer risk needs to be balanced against potential side effects, the authors warn.\u201d\nIt would have been easy to also mention cerebral vascular bleeds, but that\u2019s a minor point.", "answer": 1}, {"article": "_Cocaine intensely stimulates the brain's pleasure centers, producing not just a \"buzz\" or a \"rush,\" but outright euphoria. In a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high. \"We didn't expect that at all,\" Dackis says.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nThat study enrolled just 62 people, but the results were significant enough for NIH to fund new research _ at Pennsylvania, the University of Texas in Houston, Boston University and other sites _ enrolling about 650 cocaine users to see if modafinil really does work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention the incidence of side effects in the pilot study or from other trials. Insomnia is mentioned in the story, but we\u2019re not told how common this is in people who take the drug for withdrawal symptoms of cocaine dependence. Side effects were twice as common in the treatment group in the pilot study and included nausea, anxiety, tachycardia, loss of appetite and urinary tract infection. ", "answer": 0}, {"article": "\"Because of salsalate's anti-inflammatory effects, our results suggest that inflammation plays a role in the pathogenesis of type 2 diabetes and that anti-inflammatory therapy may be useful for treating diabetes,\" write researchers Allison B. Goldfine, MD, of the Joslin Diabetes Center in Boston, and colleagues. \"We are conducting a larger trial involving more patients with type 2 diabetes to further establish whether a salsalate dosage of 3.5g/day provides durable and safe control of blood glucose in this population.\"\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes. But the results do merit further research.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels. Salsalate contains the same active ingredient as aspirin but is associated with fewer side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms were not quantified, we give the story the benefit of the doubt for discussing potential safety issues prominently in the study, including a very early mention of proteinuria and the need for more long-term safety data.", "answer": 1}, {"article": "The therapy continued with the parents for the next six months with less intensity. At the end of the first year, the researchers could see the children had improved, but the most dramatic development was seen at the follow-up six years later. At the start of the trial, 50% of those in the control group who did not get the therapy and 55% of those who did were assessed as severely autistic. The children in the intervention group, though, got better. The proportion assessed as severe in the control group was 63% by the end of six years, compared with 46% in the intervention group.\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThis is not a cure, in the sense that the children who demonstrated improvements will still show remaining symptoms to a variable extent, but it does suggest that working with parents to interact with their children in this way can lead to improvements in symptoms over the long term.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes\u00a0an outside expert\u00a0who notes that the training intervention was non-invasive and non-intensive.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "However, nearly 46 percent of low-risk women aged 50 to 59 were screened, as were 59 percent of low-risk women aged 60 to 64.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention a potential harm common to all screening tests \u2014 the risk of a false-positive result that can lead to more tests and unnecessary treatment. And while the dose they provide is small, DXA tests do involve\u00a0radiation exposure. The story makes no mention of any possible downside to that exposure.", "answer": 0}, {"article": "For more information on men's health, visit the Endocrine Society's centennial website.\nResearchers stopped enrolling new participants in the study in 2011 due to the rate of adverse events, particularly depression and other mood disorders, reported by the participants. The men reported side effects including injection site pain, muscle pain, increased libido and acne. Twenty men dropped out of the study due to side effects.\nOf the 1,491 reported adverse events, nearly 39 percent were found to be unrelated to the contraceptive injections. These included one death by suicide which was assessed not to be related to the use of the drug. Serious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release discusses adverse effects. It says researchers stopped enrolling new participants in 2011 due to the rate of reported side events, particularly depression and other mood disorders. It also mentions that men reported having injection site pain, muscle pain, increased libido and acne, and that 20 men dropped out due to adverse effects. It also says serious adverse events that were assessed as probably or possibly related to the study included one case of depression, one intentional overdose of acetaminophen, and a man who experienced an abnormally fast and irregular heartbeat after he stopped receiving the injections.\nFurther, it quotes a researcher saying that \u201cthe combination of hormones needs to be studied more to consider a good balance between efficacy and safety.\u201d\nDespite the attention to side effects there were a few gaps. The release didn\u2019t quantify the number of men who developed depression. It noted there was one suicide among the study group, but stated it was determined not related to the hormones. How was it determined that the injection did not contribute to the suicide when the hormone shots did contribute to mood disorders? The release doesn\u2019t say.\nThe news release also doesn\u2019t adequately explain the need to cancel the study due to harms. When compared to the side effects of other hormonal contraceptives used by women it appears to be safer.", "answer": 1}, {"article": "Watch a video about research at WPI related to this study.\nWeathers says the superior performance of DLA in comparison to ACT, as well as its ability to kill drug-resistant parasites and avoid the resistance trap, itself, is likely due to the synergistic effects of a complex array of phytochemicals contained in the plant's leaves, several of which are also known to have antimalarial properties and others of which may act both to enhance the absorption of artemisinin into the bloodstream and bolster its effectiveness against malaria. In effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\nDetails of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v. artesunate: case reports\" by an international team lead by Pamela Weathers, PhD, professor of biology and biotechnology at Worcester Polytechnic Institute (WPI), who has pioneered the use of dried leaves of Artemisia annua (DLA) as a malaria therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We expect releases to state \u201cthere are no known harms\u201d if that is the case, but this story does not mention potential harms at all. The story speculates that the stronger value of the dried-leaf product may come from other phytochemicals (not named) that are in the leaves. What if one or more of those have other impacts on patients months from now? Just because a drug is \u201cnatural\u201d\u00a0doesn\u2019t mean it is free of side effects.\nMemorial Sloan Kettering has studied artemisia annua and states that people taking antiseizure medications should avoid artemisia since it can induce seizures and make these medications less effective.", "answer": 0}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe new drug is no miracle cure and it is not approved for young children, who are one of the most vulnerable groups, so the C.D.C. still strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country. Genentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue head on, earning it a solid satisfactory rating from us. One point that would have made it even stronger would have been to note that the company selling Xofluza\u00a0warns that pregnant women and nursing mothers may want to avoid the drug, as it is not known whether the drug may harm the fetus or if it would pass into breastmilk for nursing mothers.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms at all. One of the most important aspects of clinical trials is determining whether an experimental drug causes significant side effects. And at least one of these drugs is associated with brain swelling associated with headache and confusion. To be clear, this is not about asking reporters to paint a grisly picture of potential harms. If a drug had no adverse side effects, that\u2019s great \u2014 but tell readers that. And if a drug does have adverse side effects, tell readers that too.\n[Editor\u2019s note: An updated version of the story now includes the following line:\u00a0\u201cSome patients receiving solanezumab experienced swelling in the brain and other adverse events, but researchers said the drug was generally well tolerated.\u201d This line was not in the version of the story that we originally reviewed. We applaud any effort to get better, more complete information to readers. But such updates do miss readers like us who only saw the original version of the story.]", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\nSince the study was limited to young children with mild persistent asthma receiving asthma controller therapy, the authors also note that their findings may not apply to other age groups or children with more severe asthma. Further studies will be necessary to answer those questions.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by the number of asthma exacerbations, percentage of days with full asthma control, use of \u201crescue\u201d medication and unscheduled healthcare visits for asthma. As mentioned in the \u201cQuantify Benefits\u201d section, this release\u00a0includes quantitative data from the original study in easy-to-read bullet form. Furthermore, the headline and quotations used in the news release reinforce the study\u2019s findings, making it clear that acetaminophen does not worsen asthma symptoms in children.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions overdiagnosis and a couple of its consequences.\nTo better communicate harms, it could have used some outside expert commentary about the numerous risk factors and comfort levels women and their physicians have when considering the frequency of mammography; and about the fact that there are no definitive answers about the ideal screening protocol for any individual woman.\nThe article also should have included specific information from the journal article about the economic costs of biopsies and other enhanced screening. While it\u2019s hard to quantify the emotional and psychological costs to women who undergo biopsies that are found to be negative, it is possible to quantify the economic costs to a person and to the larger healthcare system.", "answer": 1}, {"article": "The key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot. Traditional guidelines have set a limit of six hours after stroke symptoms begin, and said after that it would be too late to help.\n\u201cThese striking results will have an immediate impact and save people from lifelong disability or death,\u201d Dr. Walter J. Koroshetz, director of the National Institute of Neurological Disorders and Stroke, said in a statement. \u201cI really cannot overstate the size of this effect.\u201d\nThe study showed that the time window could be expanded to 16 hours. However, the findings do not apply to every stroke victim. The researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored. Only about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Aside from acknowledging that not all stroke patients who fall in the extended time frame are eligible for this procedure, no harms were discussed. What are the harms of standard medical therapy for stroke, therapy plus thrombectomy surgery, and the special brain imaging?", "answer": 0}, {"article": "Researchers focused on two biomarkers previously thought to be involved in Alzheimer's disease: a kind of protein called beta-amyloid, and another protein type called tau. Experts believe a decrease in beta-amyloid in the fluid of the spinal cord is associated with a toxic buildup of that protein in the brain, which causes the formation of plaques linked to Alzheimer's disease. Tau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer's also.\nWhen these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk. But it's too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\n\"What I tell people is: If they\u2019re worried about their thinking abilities, that they should make an appointment with a neuropsychology or a neurologist to get an evaluation,\" Brinkman says. \"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did make several stabs at touching on harms, reporting:\n\u201cSome of the participants, who were originally found to be stable with mild cognitive impairment after about five years, went on to develop Alzheimer\u2019s disease during the longer follow-up.\u00a0 That suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer\u2019s disease, researchers say.\u201d\nAnd it did end with this:\n\u201cAs scientists gain more insight into predicting Alzheimer\u2019s, aging adults may struggle with the question of whether they want to know their risk,\u00a0 especially since there\u2019s still no cure.\u00a0 Some people want to enroll in clinical trials as soon as they start showing symptoms; others would rather be ignorant of their status since there is no cure.\u201d\nWe think these could have been framed more clearly as potential harms, but we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "But not all scientists agree that screening is a good idea. For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that cholesterol-lowering drug treatment in children is controversial and the safety of such treatment has not been studied in children. However, the story does not mention any of the specific harms of statin treatment that have been identified in studies of adults.", "answer": 1}, {"article": "The finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal. All that's needed is a little help from one's own heart stem cells.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study. He invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired. Earlier work in patients with heart failure, using different stem cells or bone-marrow stem cells, also showed that the heart can regenerate itself.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story. Bloomberg BusinessWeek reported on the same study and said, \u201cA year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart.\u201d\n\u00a0", "answer": 0}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m. ET on CNN.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nA control group advised to eat a vegetarian, low-saturated diet but not with the cholesterol-lowering foods a saw a slight dip in total cholesterol, from 249 to 246, and in LDL, from 167 to 161.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the safety of the diet. The study paper notes that there were some potential allergic reactions in the portfolio diet group.", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\nThe study included 150 pregnant women diagnosed with major depressive disorder. Some received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While acupuncture is generally safe, the story should have mentioned that 21 women in the study reported transient pain at the site of needle insertion and 1 woman experienced bleeding. ", "answer": 0}, {"article": "High blood pressure affects 1 in every 3 adults in the United States, according to a fact sheet by the Centers for Disease Control and Prevention. In 2013, high blood pressure was the major cause behind 360,000 deaths in the United States. Reduction in high blood pressure has added health benefits because it can potentially reduce the likelihood of heart attacks, strokes, chronic heart failure and kidney disease.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure. Participants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms that might arise from the use of web-based tools and videos, but it\u2019s hard to envision how they could harm study participants.", "answer": 2}, {"article": "This article has been updated with comment from Professor Udai Banerji\u200b.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer. The cancers had spread across the bodies of each participant, who did not respond to standard treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not mentioned. According to the study, the most common side effects were fatigue, nausea, anemia, and diarrhea.", "answer": 0}, {"article": "\"After the first group completed their three months on the fasting diet, we moved over participants in the control group to see if they also would experience similar results,\" Longo said. \"We saw similar outcomes, which provides further evidence that a fasting-mimicking diet has effects on many metabolic and disease markers. Our mouse studies using a similar fasting-mimicking diet indicate that these beneficial effects are caused by multi-system regeneration and rejuvenation in the body at the cellular and organ levels.\nThe next step for researchers is a large, FDA phase III clinical trial to test the FMD on patients diagnosed with age-related diseases or at high risk for them. The researchers said further investigation will determine whether the benefits of the diet can continue for several months.\nThe researchers had invited participants in the study for one last set of tests three months later, at the end of the diet. The research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any potential side effects. Certain people may not be ideal candidates for an extreme low-calorie diet, even intermittently. The release does not comment on this.", "answer": 0}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection. As expected, this process is often inaccurate. If they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread. Most existing mobile health diagnostic devices, meanwhile, can only analyze one sample at a time.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease. The researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nBuying the components themselves, the research team was able to build the device for about $50, but the manufacturing cost would probably be lower than that, he said. They have filed a patent and hope to move forward with clinical trials that could lead to commercialization.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Tests, even accurate ones, have downsides which were not mentioned in this release. The release stated that the device \u201cprovided false positives only about one percent of the time.\u201d If field workers fanned out across a city and tested 100,000 people, that 1% false positive rate would mean that about a thousand people would be told they were infected when they actually were not. The release did not mention false negatives (telling an infected person that he or she is not infected).", "answer": 0}, {"article": "But other researchers have argued that resveratrol may work by activating a separate energy pathway called AMPK, which is also related to mitochondrial energy production but does not involve sirtuin genes.\n\"A mouse model is not a human being, especially when you are genetically manipulating this animal model, you want to be very careful,\" Marambaud said. \"This field has been extremely controversial. We should be very careful about claiming the importance of resveratrol for medical purposes. We have to wait and see, but this study is a big step forward.\"\nThe study is in the May 1 issue of Cell Metabolism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms, nor of the concern for potential harms in the leap from mice to humans, nor of how long and widely a substance would need to be tested in people before its safety could be projected.", "answer": 0}, {"article": "In this study, the researchers inserted a healthy gene capable of producing WAS protein into hematopoietic stem cells (the \"granddaddy\" cells that give rise to different blood cells), then transferred these stem cells back into the patient using a viral vector. A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nHowever, one of the 10 kids in the study developed acute T-cell leukemia, apparently as a result of the viral vector that was used to insert the healthy gene. The boy is currently on chemotherapy, the study authors noted.\nNeither Conley nor Sanberg were involved in the study, which is scheduled to be presented Sunday at the annual meeting of the American Society of Hematology in Orlando, Fla.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged early on and prominently that one of the study participants developed leukemia, which may have been related to the new treatment. The story probably should have mentioned that other harms might become apparent as these patients are followed further or as more patients are studied. However, we think the study went far enough to earn a satisfactory.", "answer": 1}, {"article": "For more about deep brain stimulation, visit the U.S. National Library of Medicine.\n\"The number of patients who got better increased over time, but it's not quite clear as to why,\" Mayberg said. The workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease. The cost of the surgery is about $50,000, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s just one line in the story about harms: \u201cPatients didn\u2019t suffer from side effects, she noted.\u201d The story also says, \u201cThe workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain\u2019s rhythms.\u201d If how it works is a mystery, we think a little more space should have been devoted to potential harms. There were a total of 8 adverse events related to either the surgery or the device, two of which were deemed serious (infection). The story misses these events entirely.", "answer": 0}, {"article": "to people who have serious or immediately life-threatening, inoperable melanoma that has spread, who have no alternative treatment options, and whose physicians believe the drug is appropriate. Providence Cancer Center is the only site in Oregon offering compassionate use of the drug. The Northwest's other participating centers are the Seattle Cancer Care Alliance and Swedish Cancer Institute in Seattle, Providence Cancer Center in Spokane, and Multicare Health System in Tacoma.\nSerious side effects also became clear. Nearly two-thirds of patients on ipilimumab experienced side effects caused by over-active immunity, such as severe itching, intestinal irritation and diarrhea. Researchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nMore than 600 melanoma patients took part in the ipilimumab clinical trial at 125 cancer centers in 13 countries. All patients had inoperable cancers with widespread tumors after conventional treatment. Some patients received ipilimumab alone, others it combined with a cancer vaccine called gp100, and a third group received only the cancer vaccine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job on harms as well \u2013 \"Serious side effects also became clear. Nearly two-thirds of patients on ipilimumab experienced side effects caused by over-active immunity, such as severe itching, intestinal irritation and diarrhea. Researchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\"", "answer": 1}, {"article": "Now genomics may have provided an answer.\nStill, only 10 to 20 percent of smokers actually develop lung cancer, begging the question: Why do some smokers succumb to the disease and others don't.\nWorking on the theory that cigarettes harm not only the lungs but a \"field of injury\" extending to other areas of the respiratory tract, the study authors surmised that evidence of existing or soon-to-develop lung cancer might be available further up in the airway.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed. Bronchoscopy can be risky, especially in those with already compromised lung function such as smokers.", "answer": 0}, {"article": "The only once-and-be-done-with-it option for women has been tubal ligation (\"tying the tubes\") -- surgery that renders a woman sterile. Now a procedure called Essure, recently approved by the Food and Drug Administration, gives women an alternative. The nonsurgical approach uses a hysteroscope -- a camera-tipped instrument -- to thread two small wires through the vagina, cervix and uterus and into the fallopian tubes. The wires, composed of polyester fibers and metals, cause inflammation and, over time, scar tissue that blocks the fallopian tubes, preventing sperm from reaching eggs. Women can undergo the procedure in 35 minutes in their doctor's office, under local anesthesia; they are advised to rest for 24 to 48 hours before resuming normal activity. Essure is 99.8 percent effective in preventing pregnancy -- a rate similar to that of tubal ligation, according to the manufacturer, Conceptus Inc. of Mountain View, Calif.\nWhat's New The Pill. The Ring. The Sponge. They're all temporary means of birth control -- devices you have to keep ingesting or inserting. Even the IUD can't stay in place for more than 10 years.\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked. Until then, the patient must use another form of birth control.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the possible harms of Essure. The story should have pointed out that, because the procedure is new, long-term safety is not known.", "answer": 1}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nThe review assessed a technology called Doppler ultrasound, which measures blood flow through the umbilical cord. Abnormal findings indicate that the fetus may be under stress.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that there has been concern that the use of Doppler ultrasound might increase unnecessary interventions, including cesarean section deliveries in cases where it is not actually needed. It says the studies indicated that Doppler ultrasound appeared to lead to better decisions about cesarean sections and inductions of labor. ", "answer": 1}, {"article": "Want to embed a link to this study in your story?: Link will be live at the embargo time http://jamanetwork.\nWhy The Research Is Interesting: The United States is facing an opioid epidemic with almost 500,000 individuals dying from opioid overdoses since 2000. Despite the epidemic, opioid analgesics remain a first-line treatment for moderate to severe acute pain in the emergency department. The combination of ibuprofen and acetaminophen may represent an effective non-opioid alternative.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address the harms associated with the use (or misuse) of opioid analgesics. However, the release doesn\u2019t address the potential harms from ibuprofen or acetaminophen in a meaningful way. The closest it comes is a sentence noting that \u201cfurther research to assess longer-term effect, adverse events and dosing is warranted.\u201d But there are some things we already know. As the Mayo Clinic notes, ibuprofen use may increase risk of heart attack or stroke, and may also cause stomach or intestinal bleeding. And acetaminophen can harm the liver if taken in too large a quantity. Granted, the risk of these things is low \u2014 particularly if it is used only in the short term to address acute pain \u2014 but it would have been relatively easy to address.\nThe JAMA study didn\u2019t assess harms either; still a statement to this effect could have been made.", "answer": 0}, {"article": "About 2.2 million Americans currently live with an irregular heartbeat condition, known as atrial fibrillation. Among individuals over the age of 65, it is the most common \"serious\" form of heart rhythm irregularities, according to background information in a news release from the American Heart Association.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\nTHURSDAY, May 27, 2010 (HealthDay News) -- A new approach to treating irregular heartbeats appears to have demonstrated success in halting abnormal electrical pulses in both patients and pigs, new research indicates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms. ", "answer": 0}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses this issue thoroughly. Well done.", "answer": 1}, {"article": "For more on amblyopia, visit the National Eye Institute.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that neither treatment produced significant side effects in the study, which is accurate.\u00a0It also\u00a0goes into some detail about the potential adverse effects reported previously with\u00a0patch treatment, but it doesn\u2019t mention any of the drawbacks of acupuncture that\u00a0patients might encounter outside of a study.\u00a0Notably, the\u00a0frequent treatments required by the study protocol might require taking children out of school\u00a0and cause\u00a0disruption to their education as well as the parent\u2019s employment.\u00a0The researchers\u00a0were able to\u00a0avoid\u00a0this by scheduling all appointments after school,\u00a0but parents outside of a study might not have this\u00a0much flexibility. We\u2019ll call this a satisfactory, but more detail would have been useful.", "answer": 1}, {"article": "About Mayo Clinic\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Descriptions of BMAC treatments note that there are minimal side effects, mostly pain at the injection site that lasts a few days and can be treated with painkillers. But there are potential short- and long-term complications (including infection) of bone marrow aspiration and injections into a joint which were not addressed.", "answer": 0}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it. The post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story devotes considerable space to explaining the potential problems invoked by false positives, again with facile use of numbers. The one narrative offered in the story elaborates on this element by focusing on an elderly retiree whose scan unearths a \u201chot spot\u201d on her lung that, after considerable angst and pain caused by diagnostic procedures, was found to contain no cancer.\nAnother harm that could have been added is that the screening x-ray involves radiation, which may cause cancer itself. Though the scan is \u201clow dose\u201d, it isn\u2019t \u201cno dose,\u201d and we know that screening not only will prevent death from cancer, but it will in fact be the cause of some of the cancers.", "answer": 1}, {"article": "Among 2,463 women (average age, 69 years), 1,901 completed the study. New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group. The estimated event rate for nonvertebral fracture was lower with abaloparatide vs placebo: 2.7 percent in the abaloparatide group; 3.3 percent in the teriparatide group; and 4.7 percent in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\n: This study was funded by Radius Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no significant differences in harms seen between the drugs and the placebo without describing all the side effects. But it also mentions that hypercalcemia (elevated calcium level) was lower with the new agent compared to the existing comparator drug. While this was not explained in depth, we\u2019ll give the release the benefit of the doubt for this brief mention of harms.", "answer": 1}, {"article": "It\u2019s easy to find tumor mutations if you know what to look for. \u201cThe challenge was to develop a blood test that could predict the probable presence of cancer without knowing the genetic mutations present in a person\u2019s tumor,\u201d Velculescu said.\nThere were no false positives in 44 people who did not have cancer, they said. That's important, said Dr. Wyndham Wilson of the National Cancer Institute, because there is no point detecting cancer in people if the cancer is not going to actually cause trouble.\nIt was not a slam dunk, but the test found cancer in the blood of more than half the patients who had been diagnosed with stage 1 cancer. It was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is dealing with a proposed new blood test for early-stage cancer, so it would require a blood draw.\u00a0 While the risks of problems with that is small, the larger risk is from false positives or false negatives from the test.\u00a0 The story says, \u201cThere were no false positives in 44 people who did not have cancer, they said.\u201d\u00a0 It also points our that the test didn\u2019t detect the cancer in all cases, giving readers a reasonable expectation of risk of harms from wrong results.\nIdeally the story would have included comments from a researcher not involved with the study about the sensitivity and specificity of such tests (factors that determine false-positive and false-negative rates), and how they would perform in a larger population. \u00a0The other risk here is overdiagnosis\u2013finding cancers that don\u2019t need to be treated.", "answer": 1}, {"article": "\"You would think in today's age and the way that we've improved in so many areas of medicine, women would begin questioning this, but we're finding that they're not,\" said Beth Cahill of the National Womens Health Resource Center.\nThe surgery she's upset about may be archaic - but it's very common.\n\"It makes my blood boil,\" she says. \"It does. I'm outraged about it and that's what fires my passion to get the word out.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the harms of surgery.", "answer": 0}, {"article": "Boutot, Bertone-Johnson and colleagues in the School of Public Health and Health Sciences at UMass Amherst, with others, evaluated the relationship between diet and risk of early menopause among members of the Nurses' Health Study II (NHS2), an ongoing prospective study of 116,000 women aged 25-42 when they entered it in 1989.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day. They adjusted for age, smoking, body mass index and other possible confounding factors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t discuss harms such as allergic reactions or other adverse effects from eating certain plant foods such as soy, wheat, and nuts. However, a discussion of harms doesn\u2019t seem to be warranted since the news release does not advocate consumption of a specific foods, but rather suggests that a moderate increase in a range of plant foods might offer a benefit.", "answer": 1}, {"article": "In Belgium, engineer and nuclear physicist Yves Jongen is pioneering a new therapy that targets cancers with proton radiation; a therapy that offers precision and minimal side effects.\n\"It would be much less expensive making it more possible for a hospital to afford it -- a smaller system can already treat a relatively large number of patients per year.\"\nWhile proton therapy is a giant step forward, it's not yet the magic bullet that clinicians are looking for. So far, it is not effective against all types of cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm that is suggested is the lack of availability of the treatment.", "answer": 0}, {"article": "\"But sometimes it takes an outsider,\" Stahl remarked.\nKanzius told Stahl the chemotherapy made him very sick and that he couldn't sleep at night. \"And I said, 'There's gotta be a better way to treat cancer.'\"\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects. None at all. At least that's the idea. \n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment repeatedly states that the treatment has no side effects. This is at least premature, at worst deceptive.\nThe segment should have stated that meaningful clinical outcomes (such as death and quality of life) even in animals have not been demonstrated, that little is known about the long-term effects of the treatment on surrounding tissues, and that the use of nanoparticles in cancer treatment is so new that it\u2019s premature to declare that their use in cancer treatment is without side effects. \nOne researcher interviewed makes clear that the inference that the technique does no harm to surrounding tissue is based only on \"gross inspection\" of that tissue.\u00a0 But the story simplistically states at one point, \"Kanzius put his hand in the field to demonstrate that radio waves are harmless to humans.\"\u00a0 That\u2019s not proof of anything. ", "answer": 0}, {"article": "He wants the new procedure to return his appetite to a more manageable level so that it helps the pounds stay off. \"I'm hoping that this band will not allow me to eat a whole pizza anymore,\" he says. \"Last summer I was able to eat a whole pizza again, and I was like, this can't be right.\"\nAnother difference between the band and the bypass that proves both a plus and a minus is that the band doesn't cause the dumping syndrome. That's an often frightening attack of sweating, nausea, faintness, diarrhea, cramps and rapid pulse that bypass patients sometimes suffer after eating just a bite of a sugary food -- a deterrent to consuming certain calorie-dense items.\nAlong with the risk comes the uncertainty of how well people will be able to lose -- and keep off -- weight the second time around. Not enough time has elapsed since the advent of second operations to get a long-term assessment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention the gastric banding following gastric bypass could be complicated by adhesion of organs to one another resulting from scarring from the first surgery. \u00a0And while mentioning that this might result in a longer time needed for the surgery, there was no discussion about what ramifications there might be for the patient or how often this scenario was encountered. \u00a0There was no discussion of other complication rates. ", "answer": 0}, {"article": "Dr. Biesecker acknowledged that there was no guarantee of success. He and his colleagues know the gene mutation in the Del Sontro family must be rare. Otherwise, lots of people would have early heart disease but no obvious risk factors. To keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants. That strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nStill, Mr. Del Sontro is preparing for the worst. He has life insurance and long-term care insurance.\nHis disease casts a dark shadow, not just on him, but on his entire family. At dinner one recent evening at their yellow brick townhouse in the Georgetown neighborhood in Washington, his wife, Pura, admitted to worrying, but said, \u201cWe don\u2019t talk about it a lot.\u201d She served Indian takeout \u2014 saffron rice, tandoori chicken, eggplant. Tall, slender and elegant in skinny jeans and a long beige sweater, she ate sparingly and drank a Coke Zero. Mr. Del Sontro drank only water and took small portions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are several \u201charms\u201d embedded in this story in the way it is framed \u2013 worry, anxiety, and a sense of foreboding. Yet those harms are mostly unexplored in a meaningful way.\u00a0 \u201cBetter\u201d tests won\u2019t help unless they also identify better treatments, and there is little or no critical attention paid to potential interventions here \u2013 just a tossed off one-liner about the women who gets a stent after the first episode of stable angina, and the implied sense that stenting and bypass are used to prevent heart attacks and death.", "answer": 0}, {"article": "The single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays. The main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\nThe report describes the use of the test to analyze samples from six patients. Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory. It has been truly motivating to work with a technology that will help transform the way that we monitor and treat individuals with cancer. I am excited to share our findings with the cancer research community,\" noted lead author and researcher Christina Wood Bouwens, of the Stanford Genome Technology Center and the Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The assumption here is that more regular monitoring of patients via blood samples will lead to better outcomes, when we actually know from repeated studies that more monitoring for disorders leads to more unnecessary treatments and surgeries.\nWhat is the false positive rate? The false negative rate? What are the possible clinical harms that can result from either of these scenarios?", "answer": 0}, {"article": "If tests pinpoint an autism-related chromosomal abnormality in the child, the parents are then offered testing. If a parent is also found to have the abnormality, geneticists conclude that the couple is at higher risk of having a child with autism. (The precise risk depends on what the variant is.)\n\"CMA is better, but it's not great,\" Marion said. \"The vast majority of children who have autism have no identifiable genetic markers that will help in genetic counseling for future pregnancies. That is very frustrating.\"\nBut that leaves 85 percent or more families with little explanation for the disorder, Marion said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion regarding the emotional or social ramifications associated with receiving genetic testing results.\u00a0 ", "answer": 0}, {"article": "Right now, the American Cancer Society (ACS) and other medical groups recommend that women start Pap tests at age 21 or three years after they become sexually active, whichever comes first. Those should be done every one to two years until age 30; after age 30, women who\u2019ve had three normal Pap tests in a row can be screened less often \u2014 every two to three years.\nAt that time, the task force recommended that sexually active women get regular Pap tests to screen for cervical cancer. But it said there was not enough evidence to recommend for or against newer types of testing \u2014 including HPV tests and the \u201cliquid-based\u201d Pap tests that are now more often used than the old-fashioned version.\nBut many women still do not get regular Pap screening, Whitlock pointed out. It\u2019s thought that more than half of cervical cancer cases in the U.S. occur in women who\u2019ve never been screened, or haven\u2019t been in the past five years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained the impact that false-positive tests might have if the HPV testing became routine. More women could have unnecessary biopsies to remove tissue that was not cancerous.", "answer": 1}, {"article": "White wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included past warnings about alcohol consumption for \u201cwomen intent on warding off breast cancer.\u201d", "answer": 1}, {"article": "But as successful as the drug appears to be for some patients, it may come with a significant risk. Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nReich, a partner at Dermatologikum Hamburg and professor of dermatology, venerology, and allergology at Georg-August-University in Gottingen, Germany, says that after a year of therapy, roughly 60% of the 154 patients in the briakinumab group had near or complete clearance of their skin lesions. Those same results were achieved by about 10% to 20% of 163 patients in the methotrexate group.\nThe study is published in the New England Journal of Medicine. It included psoriasis patients who were assigned to get monthly injections of briakinumab or to take methotrexate pills weekly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Weaker than the competing HealthDay story on this point.\u00a0 This story only reported \u201cpatients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\u201d\u00a0 Then, in the second last sentence of the story, it added that serious adverse events occured in 9/1% of briakinumab group and 6.1% of methotrexate group.\u00a0 But HealthDay actually quantified what they were \u2013 the number of serious infections and the number of cancers.\nIt\u2019s inadequate for WebMD to throw in a line \u201cmore cancers\u201d while failing to provide any numbers or details.", "answer": 0}, {"article": "Up until now, Bristol has dominated the field but investors have started to shift their bets, with forecasts for Opdivo declining while those for Keytruda have risen.\nThese showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant. Overall survival was 14.4 months with Opdivo versus 13.2 months.\nAnd when given with two older chemotherapy drugs in non-selected patients, it was almost twice as likely to shrink tumors as chemotherapy alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both chemotherapy and immunotherapy carry risks. But the story doesn\u2019t discuss the general potential harms of either, nor what was reported\u00a0in the study.\nAs the NEJM study offered up, \u201cserious treatment-related adverse events occurred in a similar percentage of patients in the pembrolizumab (Keytruda) group and the chemotherapy group (21.4% and 20.7%, respectively).\u201d And, \u201cdiscontinuation of treatment because of treatment-related adverse events occurred in 7.1% of patients in the pembrolizumab group and in 10.7% of patients in the chemotherapy group.\u201d\nThese serious adverse events included diarrhea and pneumonitis in the Keytruda group, and anemia, fatigue, and decreased appetite in the chemo group (among other events).\nSome independent\u00a0commentary on how these drugs impact quality of life\u2013especially for very sick patients with advanced cancer\u2013would have been very useful.", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "CPR, when performed by training medical personnel or bystanders, carries risk including broken ribs, internal organ damage and cognitive deficits. These risks are especially high for those with chronic or terminal diseases, or whose arrests already have lasted long enough to cause brain damage. The urge to \u201chelp\u201d among bystanders is powerful and praiseworthy; and Good Samaritan laws not only recognize the impulse as humane but also protect those who give aid. But a story so positive about \u00a0CPR\u2019s benefits has some obligation to alert victims and potential helpers alike of the risks as well as the benefits.", "answer": 0}, {"article": "The Buck Institute is the U.S.'s first independent research organization devoted to Geroscience - focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending \"Healthspan\", the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's, cancer, cardiovascular disease, macular degeneration, osteoporosis, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics, bioinformatics and stem cell technologies. For more information: http://www.\nLithium is a naturally occurring element, not a 'developed' molecule like most medications. It was approved by the FDA for the treatment of bipolar disorder in 1970 and has shown to be effective for treating mood disorders and suicidal thoughts. Previous studies suggest that at low doses lithium has a protective effect in other neurodegenerative diseases including Alzheimer's and Huntington's.\nLow-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is silent on the issue of the potential for toxicity with lithium augmentation. \u00a0Although the research was conducted in mice, the researchers did note the potential for toxicity in their publication, \u201c\u2026in a few reported cases lithium treat- ment was suggested to be detrimental to PD patients and to cause side effects\u2026\u201d Since lithium is also used in the treatment of psychiatric disorders, it\u2019s possible the release could have pulled from the literature on this use to discuss potential side effects.", "answer": 0}, {"article": "For decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids). The difference came down to the specific type of fats that make up these foods \u2014 animal and dairy fats tend to be saturated, which means all of the free bonds available in a chain of carbon atoms are bound to hydrogen atoms, while plant fats are unsaturated, meaning some of carbon atoms have double bonds with each other. Saturated fats are more likely to build up within artery walls and form plaques that can trigger heart attacks.\nWhether the association will change its advice about consuming linoleic acid isn\u2019t clear yet, but Ramsden says the results of the latest study \u201ccould have important implications\u201d for the way people eat if they want to stay heart-healthy.\nA study shows that not all good fats are the same when it comes to protecting your health\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall thrust of the story was about harms of linoleic acid, so we\u2019ll call this satisfactory.", "answer": 1}, {"article": "The findings showed that breast cancer risk was 12 to 19 percent lower among women who ate more dietary fiber in their youth, depending on how much more they ate. Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\nEating more fruits and vegetables was especially beneficial, the researchers said.\nWhy would these foods have such an impact?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet by eating more fruits and vegetables. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Focal Therapeutics is a medical device company based in Aliso Viejo, Calif. The company's BioZorb marker is a proprietary bioabsorbable device that provides radiographic marking of soft tissue sites. The BioZorb device is placed at the time of surgical removal of tissue, such as during breast surgery, and the device's three-dimensional array of marker clips has unique clinical utility for patient imaging. BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration. The device is available in a range of sizes to accommodate a variety of clinical situations. For more information about the company, call (U.S.) 650-530-2394 or email info@focaltherapeutics.com.\nThe article also noted that there was a shift during the three-year course of the study toward increasing use of hypo-fractionated radiation methods. These methods decrease the time it takes for patients to complete radiation treatment -- and are estimated to cut the cost of treatment by approximately 25%. The authors said use of the marker facilitated their shift toward these shorter courses of radiotherapy.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist. The study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no indication of harms in the news release. However, the original article did note side effects that arose in two patients. It would have been good to note them in the release. The published study also acknowledged that skin changes and dermal lymphedema (swelling) were a concern among patients but were not specifically tracked. Again, a mention of that in the release would have been helpful to patients.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative data indicating that the rate at which blood clot formation occurred after implanting the new stent was comparable to the rate with one of the currently available drug-eluting stents. \u00a0However there was no information about how the harms with this new stent compared with bare metal stents or no stent at all.", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a major\u00a0strength of this article. It makes it clear CAR-T treatment is not without major risks which include: treatable anemia, brain toxicity, and a \u201cdangerous condition where the immune system overreacts in fighting the cancer\u201d (likely, \u201ccytokine release syndrome\u201d). Deaths directly caused by CAR-T therapy in this and other trials are\u00a0mentioned.", "answer": 1}, {"article": "For more on breast cancer, visit Breastcancer.org.\nIn the current trial, the women who were randomly selected to receive talazoparib had a higher response rate to treatment than women who received standard chemotherapy: 63 percent versus 27 percent, the researchers found.\nIn addition, 32 percent of the women receiving talazoparib had other side effects, compared with 38 percent of those on standard chemotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the harms, notably blood disorders, and included the rate of harms in both the treatment group and the control group, which is a useful comparison to include.\nOne detail that also would have been useful to include: The rate of severe adverse events was similar in both the treatment and control groups. The drop-out rate (how many women dropped out of the study due to side effects) was slightly higher in the talazoparib group.", "answer": 1}, {"article": "At the 12th week, 82 percent of people receiving spinal manipulation reported at least a 50 percent reduction in pain, compared with 69 percent of those on medication and 77 percent doing home exercises. Also at week 12, of people receiving spinal manipulation, 32 percent reported feeling a 100 percent reduction in pain, compared with 13 percent on medications and 30 percent doing home exercises.\nBut, there isn't much evidence for treating neck pain with spinal manipulation. There also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain. This is especially true if you've been in a car accident, or if you have any neurological symptoms, such as repeatedly dropping things, or if you have pain radiating down your arm.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This rating is a close call. The story does warn readers that spinal manipulation can pose \u201crare, but serious risks.\u201d Also, none of the trial participants reported a serious adverse event. But the story could have been more specific and reported that, as the editorial accompanying the research article pointed out, \u201cneck manipulation has a rare but potentially catastrophic risk for vertebral artery stroke.\u201d Also, the story should have at least briefly mentioned some of the harms that can be caused by the pain medications (including acetaminophen, narcotics and muscle relaxants) that were prescribed to some participants.", "answer": 0}, {"article": "Merck suffered a setback last year when its attempts to win marketing approval to sell Erbitux in lung cancer were rebuffed by regulators.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\nBaselga said that level of improvement was rarely seen in this advanced-disease population and was highly promising.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "One potential harm is false positives, in which a suspicious mammogram finding leads to more tests, sometimes even biopsies, but turns out to be harmless. The guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women. Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is really a strong point for the story. The story devotes several paragraphs to explaining \u2014 and quantifying \u2014 the potential harms of false positives and overdiagnosis. It then spends an additional two paragraphs trying to place these harms in context. For example, citing a cancer expert\u2019s position that the potential harms are significantly outweighed by the potential benefits. The story also made clear that there was an emphasis in the recommendations that women be able to decide for themselves on when to begin screening, and how often to be screened. That\u2019s an important point \u2014 women should know that they have a role to play in weighing risks against potential benefits and \u2014 ultimately \u2014 making decisions about their health.", "answer": 1}, {"article": "\u201cWhen the drug company sends someone in to give them a talk and buy them pizza, they think they\u2019re getting a scientific lecture,\u201d he said.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nAfter six months, the Vivitrol group had a lower rate of relapse, 43 percent compared with 64 percent. A year after treatment stopped, there had been no overdoses in the Vivitrol group and seven overdoses, including three deaths, in the other group. The results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does make clear that evidence so far suggests that short-term use of Vivitrol does not eliminate overdoses in the longer term, it does not reflect on adverse events reported in the NEJM article as a result of the trial, which included such issues as reactions at the injection site, headaches and nausea.", "answer": 0}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nSuch research is already underway, Arnold said, but it's too early to discuss the findings.\nThursday, Woodcock held out the possibility that Avastin might eventually prove helpful in a targeted group of patients. \"We certainly hope that additional data could be generated to see if there is a subset of tumors (that would respond more than others),\" she said. \"The FDA stands ready to work with Genentech on future studies.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not quantified, and it would\u2019ve been very helpful to know how frequently these serious side effects occurred in the trials. Were they exceptionally rare? Utterly rampant? The point of our criterion is that without quantifying the harms, readers can\u2019t evaluate the risk/benefit trade-off for themselves.\nThat said, we could almost award\u00a0the story credit on the spirit of this criterion because it gives the serious harms, and their implications in the FDA decision, a solid amount of time in this article. The point from the ACS medical officer that some women \u201chave not only not benefited, they\u2019ve been harmed,\u201d conveys the big picture.\nHowever, true to the definition of this criterion, we must grade this as unsatisfactory.", "answer": 0}, {"article": "She agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk. She calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\nKeeping blood pressure controlled, not smoking, exercising regularly, and eating a healthy diet that is low in salt and rich in fruits and vegetables can also help reduce stroke risk, she says.\nCathy A. Sila, MD, the George M. Humphrey II Professor of Neurology and the director of the Stroke & Cerebrovascular Center at the Neurological Institute Case Medical Center of Case Western Reserve University School of Medicine in Cleveland, Ohio, says the benefits of diet and lifestyle choices in disease prevention are more important than ever, given the rising costs of health care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "\"Close to a million tons of equipment,\" Metz said.\nThe technology is two decades old, but Mass. General is one of five proton centers, and there are eight others in the works.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of proton beam therapy.", "answer": 0}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles. \u201cFor patients, this is a really hopeful thing.\u201d\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, although they are important, especially considering the failure of the therapy to improve secondary outcomes.", "answer": 0}, {"article": "Fibromyalgia is characterized by widespread pain, fatigue, insomnia and multiple tender points. The syndrome can also cause psychological issues, including anxiety, depression, and memory and concentration problems, sometimes called the \"fibromyalgia fog.\"\nPrior research has shown exercise can improve mood, Wang added. The controlled breathing and movements may promote \"mental tranquility,\" according to the study, which could help with pain.\nResearchers divided 66 people with fibromyalgia into two groups: one group did hour-long sessions of tai chi twice a week for 12 weeks; the other had a twice-weekly wellness education class followed by gentle stretching.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not identify any possible harms. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The NEJM authors clearly state: \"No adverse events were noted during the study interventions.\" The study did not consider worse muscle soreness to be an adverse event so long as it resolved before 3 days\u2019 time, so we don\u2019t know how much of that occurred in either arm of the study. So why not drop in a line about the lack of adverse events? Wouldn\u2019t a reader be interested that this exercise appears safe?", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The WSJ article very explicitly notes that there are harms from invasive prenatal tests, although it does not give rates of miscarriage; and it goes into welcome detail about the challenges of giving women genetic risk information for themselves or their infants based on the noninvasive blood test, noting \u201cthere is no consensus on when or how to inform\u201d patients of such findings. On the other hand, the story explains, if maternal tumor DNA is detected, the need to inform the mother may be urgent and life saving.", "answer": 1}, {"article": "Scientists at the University of Warwick and spin-off company Medherant say their TEPI patch could revolutionize the transdermal drug delivery market.\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\n\u201cWhat we do is dissolve the active ibuprofen, for example, into the adhesive so we can have quite a high loading - so up to 30 percent of the adhesive will be the ibuprofen,\u201d said Haddleton. \u201cWhen that\u2019s placed on the skin just like an elastoplast then the drug will actually diffuse across the skin into the body at the site of the pain and then relieve the pain in the same way as current gels and creams. We\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information on the potential side effects of this method of drug delivery. Ibuprofen is a drug and all drugs have side effects. It sounds like the TEPI patches will have the same possible side effects as topical gels or other patches, which are mostly limited to irritation on the skin and other minor issues. It is claimed that the TEPI patches cause little discomfort, but how was this assessed?", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown. \"Typically, immune cells from solid tumors, called tumor-infiltrating lymphocytes, can be harvested and grown in only about 25 percent of patients who could potentially be eligible for the therapy. But in our clinical trial, we were able to harvest and grow MILs from all 22 patients,\" says Kimberly Noonan, Ph.D., a research associate at the Johns Hopkins University School of Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nNoonan says the small trial helped her and her colleagues learn more about which patients may benefit from MILs therapy. For example, they were able to determine how many of the MILs grown in the lab were specifically targeted to the patient's tumor and whether they continued to target the tumor after being infused.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this criterion a satisfactory rating since the release specifically spells out, \u201cNone of the participants had serious side effects from the MILs therapy.\u201d However, the study is really too small, and the time\u00a0span too short, to comment substantively on the possible harms that might be seen if and when the treatment is more widely used. The research paper actually makes the point that the new procedure doesn\u2019t require the \u201csurgical removal of tissue,\u201d and the procedure can be done at bedside rather than an operating suite. But\u00a0the removal of cells from the bone marrow is still an invasive procedure that carries its own risk of infection or other problems. The release would have benefited from at least mentioning this aspect.", "answer": 1}, {"article": "Further, allergy challenge tests showed a decrease in airway reactivity among patients taking Gleevec, the researchers reported. Airways became less likely to close off after exposure to an allergen.\nBut, this powerful cancer drug can't be recommended for them on the basis of this small study, Israel and other specialists noted.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely passes the bar on this one, reporting that side-effects \u201cwere not as severe as expected.\u201d It adds: \u201cOne person dropped out because of a sharp decline in white blood cells, which bounced back after the drug was discontinued. Another person dropped out because of leg cramps associated with the drug.\u201d\nIt also quotes an independent expert saying the drug is \u201ctoxic.\u201d For lay readers, that might be a confusing term.\nAlso, there\u2019s no mention of the general risks of imatinib, which include infections, bleeding, liver problems, and heart problems. The fact that this is a type of chemotherapy could have been mentioned, too.", "answer": 1}, {"article": "The drug is approved by the FDA only for traveler's diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD. For those with this type of IBS, symptoms can include abdominal pain, bloating, and changes in bowel function such as diarrhea.\nWith the new antibiotic treatment, Pimentel tells WebMD, many participants ''say they are 80% improved, 90% improved, that kind of results. The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The main problem is that there was no explicit statement about presence or absence of side effects. Readers want to know, and since researchers have studied and reported on adverse effects, there should be an explicit mention in a news report. In this case, there was no difference in side effects between the drug group and the placebo group.", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says the test\u2019s ability to diagnose normal moles was 36 percent, \u201capproaching the levels achieved by expert dermatologists performing visual examinations of suspect moles under the microscope.\u201d\nBut as noted above, that statement downplays the fact that the test will result in a very high number of false-positives. A 36% specificity means that nearly two thirds of non-malignant moles will test positive and require additional follow-up. A test that correctly identifies nearly all melanomas, but also flags more than half of normal growths as melanomas, isn\u2019t all that useful.", "answer": 0}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention important harms of the various medications that might go into the pill. We\u2019re told only that \u201cthe doses are low, so it\u2019s relatively safe.\u201d We wanted to see a nod to side effects, risks and trade-offs of using these drugs\u00a0in a broad preventive manner.\u00a0Taking a baby aspirin every day, for example, can increase the risk of serious gastrointestinal bleeding, which is why guidelines don\u2019t recommend that everyone over 50 take them.\nThe story does state that a polypill might actually backfire by causing people to think it will protect them, and therefore they exercise less and eat worse.", "answer": 0}, {"article": "\u201cTake charge of your biological clock,\u201d the invitation urged.\nSo a patient may see a table showing that her genetic variants make her twice as likely to have a condition known as recurrent pregnancy loss, defined as repeated miscarriages. But the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor. The doctor ordering the test, or a genetic counselor, is supposed to provide that information.\nThe company\u2019s website also features testimonials from women who say they have used Fertilome to help guide their decisions. There\u2019s Ella, a 30-year-old with dark hair and stylish clothing who decided to freeze her eggs after taking the Fertilome test. Then there\u2019s Maxine, a 27-year-old medical school graduate with short hair and a warm smile who used the test to help her juggle the timing of starting a family and starting her career.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the strengths of this story is its explanation of the actual risk to a woman with a particular genetic variant identified by the test.\u00a0 The test results cast risk in terms of relative likelihood (i.e., they determine if a woman is more likely, as a result of a genetic variant, to develop a specific condition that could affect her ability to get pregnant) while the story supplements that with numbers characterizing the \u201cabsolute\u201d risk (that condition is rare in the first place, so even an increased risk is small in absolute terms). \u00a0Sources in the story also identify another harm: misinterpretation of results can heighten anxiety. The story could have gone further, to contemplate the possibility that women may make wrong decisions based on the incomplete information provided by the test.", "answer": 1}, {"article": "The World Health Organization describes childhood obesity as one of the most serious public health challenges of the 21st century, with an estimated 41 million children under the age of 5 falling into this category. Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari. \"However, if your child is overweight or obese I recommend that you consult your primary care physician for advice, and consider having their vitamin D levels tested.\"\nProfessor Mary Fewtrell, assistant officer for health promotion at the U.K.-based Royal College of Paediatrics and Child Health, told Newsweek: \"Although the effect sizes are not given, these outcomes are certainly positive. It's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possible harms of taking too much vitamin D are fairly well-known for adults, less is known about how it affects kids. Nevertheless the harms are\u00a0numerous and significant. At least a small sample of those risks should have been included in the story, e.g. putting too much calcium in the blood, a greater risk of forming kidney stones, and a greater risk of developing kidney diseases.\nThe story did at least point out \u201cthere remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency.\u201d", "answer": 0}, {"article": "\"We wore masks, we had hand sanitizer, we had raw hands from cleaning so much,\" Vaccaro recalled.\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA. His treatment involves taking bone marrow from the patient to gather stem cells. A cloned gene is then added to correct what was missing at birth.\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness. It affects cells that play important roles in helping the immune system battle bacteria, viruses and fungi that can cause infections. Even the common cold can be deadly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed in any way. With such a serious disease, harms would have to be significant to outweigh the potential benefits, but they should still be mentioned.\nThe story\u2019s depiction of the procedure doesn\u2019t convey the full scope of what\u2019s involved. It states, \u201c\u2026.the\u00a0treatment involves taking bone marrow from the patient to gather stem cells. A cloned gene is then added to correct what was missing at birth\u2026\u201dThose stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient\u2019s life.\u201d Although it sounds pretty straightforward, a look at the actual procedure as listed at ClinicalTrials.Gov\u00a0provides a more complete picture. The stem cells are collected under general anesthesia and treatment with busulfan (which can cause significant side effects) to reduce bone marrow cell production in preparation for the stem cell infusion.", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes sources claiming \u201cYou\u2019re going to be sparing individuals side effects\u201d and it describes Xalkori as \u201ca pill with relatively minor side effects compared to the hair loss and nausea that chemotherapy can cause\u201d. The drug label and FDA news release are less dismissive of the problems experienced by patients in the preliminary trials so far.\nWhile few trial participants reported symptoms severe enough to cause serious harm, hospitalization or symptoms so bad they couldn\u2019t carry on routine activities, most of the patients did report problems with vision and more than half reported nausea, diarrhea, vomiting or other gastrointestinal symptoms, including some that may have required treatment. Treatment was interrupted in 36 percent of the patients in one of the trials and 45 percent of the patients in the other trial. Five percent of patients had neutropenia, abnormally low white blood cell counts. (See http://labeling.pfizer.com/showlabeling.aspx?id=676) \nThe FDA news release included a list of side effects and warned of potentially life-threatening reactions. \u201cThe most common side effects reported in patients receiving Xalkori included vision disorders, nausea, diarrhea, vomiting, swelling (edema), and constipation. Vision disorders included visual impairment, flashes of light, blurred vision, floaters, double vision, sensitivity to light, and visual field defects. Xalkori use has also been associated with inflammation of the lung tissue (pneumonitis), which can be life-threatening. Patients with treatment-related pneumonitis should permanently stop treatment with Xalkori. The drug should not be used in pregnant women.\u201d (See http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm)\nThe story should have summarized these side effects and warnings. It should have also noted that since the trials reported by Pfizer included only 255 patients, little is known about the potential risk of rare, but serious, side effects.", "answer": 0}, {"article": "The study also concluded that participants who underwent positive lifestyle changes delayed type 2 diabetes by about four years, compared with the control group. Benefits of intensive lifestyle changes were most pronounced in the elderly, with people 60 or older reducing the rate of developing type 2 diabetes by half.\nThe study is published online today in the The Lancet, a medical journal.\nJohn Held, with a family history of type 2 diabetes, watched as his own blood-sugar levels crept over the normal range, identifying him as a prime candidate for the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the side effects of metformin, which include gastro-intestinal side effects that can inhibit compliance. A serious condition, lactic acidosis, is a rare but significant side effect.\n\u00a0", "answer": 0}, {"article": "Turner likens the use of the VIPS device in detecting severe stroke to the use of electrocardiography (ECG) to definitively detect acute myocardial infarction. He predicts that the device has the potential to be used widely by emergency personnel but also to appear in other public spaces. \"This could potentially be something like a defibrillator,\" said Turner. \"You can find out if a patient is having a stroke, just like you can put a defibrillator on a patient to see if they're having a heart attack.\"\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field. This is because the accuracy of the device simplifies the decision made by emergency personnel about where to take patients first, according to Raymond D. Turner, M.D., professor of neurosurgery and chief of the Neuroscience Integrated Center of Clinical Excellence at MUSC. Turner served as principal investigator for MUSC in the VIPS for the Non-Invasive Detection of Hemispheric Bioimpedance Asymmetry in Severe Brain Pathology (VITAL) study reported in the article.\nThe device's success may be found in its ability to give emergency personnel a clear answer as to whether a patient is experiencing a severe stroke. The VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in this news release. One big concern with both diagnostic and screening tests is the consequence of a false negative test result which could lead to a patient receiving the wrong, unnecessary or no treatment.", "answer": 0}, {"article": "But not a whole lot.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note. They add it is currently unclear what dose and particular formulation of the supplement will be most helpful.\nThe new review is based on 13 trials with 966 participants who either took zinc or a dummy treatment at the beginning of their symptoms. Another two trials found that zinc helped stave off colds, but the quality of that research was low.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did discuss the side effects. This story says, \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\u201d\u00a0The full listing in the article includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. Because the story downplayed the side effects in a story that is essentially encouraging long-term zinc use, we rate this unsatisfactory.", "answer": 0}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are called out clearly starting with the headline, which reads: \u201cIs Peru\u2019s Psychedelic Potion a Cure or a Curse? Foreigners are flocking to try a traditional brew called ayahuasca that some say eases psychological distress \u2014 but it has dangers, too.\u201d\nThe story mentions vomiting as a common reaction in the third paragraph. More serious risks are addressed in paragraph nine, which says \u201csome scientists \u2014 and users \u2014 warn that ayahuasca can be dangerous. It can be fatal when mixed with other drugs, such as antidepressants, and should be avoided by those who are bipolar or schizophrenic, since it has been known to trigger psychotic episodes.\u201d\nThe story also tells of purported deaths related to ayahuasca use, but these incidents are not flushed out in detail, leaving the reader to wonder about their significance. It paraphrases comments from a U.S. Navy official who says DMT can cause seizures, comas and respiratory arrests and lead to hallucinations that \u201ccan be so traumatic that they can worsen medical conditions such as PTSD.\u201d Another user mentions \u201cnightmarish hallucinations.\u201d\nHowever, there are no firsthand accounts of these known harms,\u00a0unlike the many accounts of positive experiences.", "answer": 1}, {"article": "The sweating can occur even when the temperature is cool and the person is at rest. The armpits, palms, and soles are often affected.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201csome in the study reported temporary tenderness, redness, numbness and bruising.\u201d That\u2019s all it said.\nThat raises more questions than it provides answers.", "answer": 0}, {"article": "TEL AVIV (Reuters) - Israel-based Neuronix, which has developed a non-invasive medical device to help to treat Alzheimer\u2019s disease, expects the system to be approved by the U.S. Food & Drug Administration in late 2014.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said. \u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\nPascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement. Their improvement was significantly more than the average seen in patients taking just medication, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t know how complete is the list of complications reported when the data haven\u2019t been published yet and we\u2019re hearing this only from the company and/or a company-supported investigator.\u00a0 The story stated that \u201cabout 20 percent of patients experience a mild headache but there are no long-term negative effects.\u201d Why would this approach cause headaches?\u00a0 How can you discuss \u201cno long-term negative effects\u201d after short-term results in 6 people?\nThe story should have painted a picture of how incomplete the harms picture is at this point.", "answer": 0}, {"article": "In laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs. The laparoscope is a slender tube that allows the surgeon to see inside the body. Most minimally invasive prostate operations are robot assisted.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explictly compares the harms of the two surgical approaches in terms of short-term complications and longer-term consequences. ", "answer": 1}, {"article": "Beyond walking, weight lifting and other resistance training may improve bone mineral density in the lower back, and maintain bone density in the hips. Resistance equipment that addresses this area includes the back extension, abdominal and leg press, hip abduction and adduction, and hamstring and gluteal press machines. Other exercises - such as front and lateral raises with free weights - focus on the spine at chest level.\nIf you already have osteoporosis, check with your doctor before embarking on a weight lifting program because if you try to lift too much weight too soon, you could fracture a bone. But remember: Not exercising also puts you at risk.\nAnd walking, though not as good for bones as jogging or jumping, is far better than just standing, he said. \"It's the cyclic loading and unloading of weight, not simple compression, that keeps bones strong,\" he added. If a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note that that fractures can occur as a result of weight lifting.\u00a0 But the focus of the column was on walking, and it didn\u2019t discuss the possibility of falling during walking and the importance of good footwear and a clear walking area.\u00a0 \nIt also concludes with the following statement: \u2018Not exercising also puts you at risk\u2019 \u00a0\u00a0This raises questions such as \u2013 at risk of what, and how great a chance is there of that happening, and to what extent it that chance diminished by exercising?\u00a0\n\u00a0", "answer": 0}, {"article": "Cystic fibrosis is a genetic disease that causes problems with the balance of salt going in and out of cells. A sticky mucus clogs organs, particularly the lungs and liver. It can also cause digestive problems. About 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation, and the average person with the disease dies before age 40.\n\u201cWe have an incredible proof of concept,\u201d Beall says. He points to other research under way with ivacaftor combined with another drug that could help people with the most common mutation of cystic fibrosis. That trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\n\u201cThis is the first time that we have a therapy that is directed at the cause of cystic fibrosis,\u201d says Dr. Michael Konstan, the chair of the Department of Pediatrics at Rainbow Babies and Children\u2019s Hospital in Cleveland and one of the authors of the study. There is no cure for this disease and existing treatments just help alleviate some of the symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not make any reference to harms. Although the journal article reporting the trial findings says that the patients receiving the active drug generally had fewer problems than those in the placebo group and that the adverse effects were not serious enough to cause people to stop taking the drug for more than a short period, the editorial points out that this trial does not prove that long term use of this drug is safe. The story should have told readers that patients will probably need to take the drug their entire lives and that further tests are needed before long term safety questions can be answered.", "answer": 0}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did an incomplete job on side effects.\u00a0 It did mention nausea, depressed mood and skin tingling \"which led to a discontiuation rate of 9.4%.\" But the FDA has raised major concerns\u00a0about this drug and rates of depression, and that is not clear from the story.", "answer": 0}, {"article": "One characteristic often associated with acid reflux \u2014 being overweight, especially with abdominal obesity \u2014 largely explains why the condition has become so common in Western countries. Someone with a body mass index in the overweight range is almost twice as likely to have GERD as a person of normal weight. Losing weight is one of the best ways to find relief without having to rely on medication.\nIf adopting the above measures fails to fully control acid reflux, taking a proton pump inhibitor may also be needed. But a P.P.I. should be used in the lowest effective dose at the correct time and for the shortest possible period, experts say. \u201cStudies have revealed that 80 percent of Americans may be taking these powerful meds incorrectly,\u201d Dr. Aviv wrote. He said they should be taken 30 to 60 minutes before eating breakfast or dinner (or both), but not used as an \u201cantidote\u201d to consuming acidic foods.\nQuitting smoking, limiting alcohol and avoiding carbonated drinks are also important protective measures. Smoking and alcohol can loosen tension of the upper esophageal sphincter and cause symptoms of reflux like hoarseness, postnasal drip and shortness of breath by irritating the mouth, larynx and trachea, Dr. Aviv reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms. However, it\u2019s difficult to think of harms associated with quitting smoking, reducing alcohol intake or eating a healthier diet. There may be harms associated with not addressing GERD if lifestyle changes are not adequate, but the story does note that patients may need to take PPIs if lifestyle changes are insufficient. Ergo, the story earns a satisfactory rating here.", "answer": 1}, {"article": "There may even be a reason to start for people in their late 30s and up, he says. \"Aim for an average of three, 8-ounce cups of coffee per day in the morning after eating breakfast.\"\nIn the study, blood levels of caffeine were more than 50% lower among people with MCI who developed Alzheimer's during follow-up, when compared with their counterparts who did not worsen. Coffee was the main, or only source, of caffeine among people in the study.\nAlzheimer's disease is the most common type of dementia. Symptoms include serious memory loss, confusion, and mood changes that develop gradually and worsen with time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Caffeine can cause anxiety, poor sleep, irritative bladder symptoms, palpitations, and even arrythmia. \u00a0Older people are at greater risk for each of these problems and should be aware of the adverse effects of caffeine, even at lower levels of intake.", "answer": 0}, {"article": "First, they looked for a biomarker \u2014 an electrical blip that appears in the brain just before the animal reaches for fatty food. Next, the researchers programmed the stimulator to deliver a 10-second pulse whenever it detects this biomarker. They rigged some mice to this intermittent stimulator. For comparison, other animals got continuous DBS stimulation or random pulses.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior. That got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video. Plus, the treatment seemed specific to the food addiction. It did not affect anticipation associated with normal behaviors such as meeting a new mouse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss harms. Bleeding in the brain, infection, and device failure are all known risks. This would have helped balance out the researcher\u2019s unchallenged assertion that this procedure is \u201csafe.\u201d This is especially important to balance when talking about medical devices, which are not as regulated as drugs.", "answer": 0}, {"article": "Tiotropium bromide (Spiriva)) belongs to a class of drugs called anticholinergics, which work by enlarging the airways to allow for easier breathing. Currently, the U.S. Food and Drug Administration has only approved the medication for use by patients with chronic obstructive pulmonary disease (COPD), a chronic ailment that is a combination of bronchitis and emphysema.\nThat's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists. These drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms in the study aren\u2019t quantified. How often did they occur? It tells us that the long-term safety needs to be studied, and it gives us good points about safety concerns that have been raised about Severent. (The AP article we reviewed mentions the safety concerns that have been raised about Spiriva.) We think safety information from this study, including the rates of serious events, could\u2019ve been mentioned if not quantified.", "answer": 0}, {"article": "While Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications. Some weight loss experts say making Orlistat available directly to consumers broadens the proven options available to people trying to reach a healthier weight. \"It's very exciting,\" Klein says.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says. They range from flatulence and increased bowel movements to diarrhea and anal leakage.\nMore than 100 studies involving some 30,000 patients have been conducted with Orlistat, according to GlaxoSmithKline (GSK) Consumer Healthcare, the maker of Orlistat, which has petitioned the FDA to permit OTC sales of the drug. The company says that 22 million people in 145 countries have taken the drug. \"Orlistat is a very safe and effective drug with a long history of use around the world,\" says George Quesnelle, president of GSK Consumer Healthcare, North America.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that about 70% of users experience gastrointestinal \ncomplications and lists some. ", "answer": 1}, {"article": "Enzyme blockers work like keys in locks. Most drugs in development have been so called active site-directed inhibitors, which act like master keys and lock the entire enzyme, blocking both its disease-relevant functions such as collagen degradation and its other normal functions.\nThe treatment could also potentially be used to treat a variety of other bone and cartilage diseases such as arthritis and certain bone cancers.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned. According to WebMD, red sage: \u201ccan cause some side effects, including itching, upset stomach, and reduced appetite. There is some concern that it might also cause drowsiness, dizziness, and a blood condition called thrombocytopenia.\u201d The safety of long-term use hasn\u2019t been rigorously studied.", "answer": 0}, {"article": "For more information about free lung cancer screening at the Georgia Cancer Center and MCG, call 706-721-4726 or email lung@augusta.edu.\nThe pioneering National Lung Screening Trial, which began in 2002 and included 33 largely urban centers, found 292 cases of lung cancer among the 26,722 high-risk individuals screened in the first year, for a rate of 1.1 percent. That study also provided the first broad evidence that low-dose computed tomography, or LDCT, was a more effective screening tool than the traditional chest X-ray. A decade later, the Massachusetts-based Lahey Hospital & Medical Center, on which the Augusta screening was modeled, found a .6 percent prevalence in the first 10 months of screening.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used. The group recommends screening for those age 55-80 with a 30-pack year or greater history who have stopped smoking for 15 years or less and those age 50 or older with a 20-pack year smoking history and an additional risk factor other than secondhand smoke, such as family history of lung cancer or a personal cancer history. A pack year means smoking one pack a day for 30 years, or a variation like two packs daily for 15 years. After 15 years of not smoking, the lung cancer risk tends to diminish but never vanishes. Schroeder would prefer the screening still not stop there.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CT scans expose a patient to a significant amount of radiation, which this release doesn\u2019t address at all. Do the benefits of a potential early diagnosis outweigh the risks associated with radiation exposure? That\u2019s for each patient (and his or her physician) to decide. But a patient needs to be aware of those risks in order to make an informed decision.\nIn addition, an important limitation was not addressed in the release (nor was it spelled out in the study abstract). According to a 2017 article in the journal Chest, \u201cA significant limitation of lung cancer screening is the false-positive rate. One of the major concerns with the NLST [National Lung Screening Trial] has been the high false-positive rate of screening with LDCT (27.3%).\u201d", "answer": 0}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said. \u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\nThe authors acknowledged certain weaknesses in their study. For example, they did not examine the safety of the herbal remedy, only its effectiveness.\nDr. Barrett said there was probably little harm in using echinacea, and he was cautiously optimistic that the herb does have a very small positive effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0points out\u00a0that the herb has some side effects, and quotes a physician mentioning the most common one (a rash, especially in children) and the most important contraindication (pregnancy).\u00a0It also points out that the study did not take potential harms into account, alerting readers to the possiblity of others\u00a0not mentioned here.", "answer": 1}, {"article": "About The Annals of Thoracic Surgery\nThe study also showed that the 30-day stroke risk was 3.6% in TF-TAVR patients and 2.0% in TA-TAVR patients. Major complications, such as bleeding or vascular issues, occurred in 35% of TF-TAVR patients and 32% of TA-TAVR patients, and more than 80% of patients were discharged home after the procedure.\nFor the study, the researchers used two different approaches: transfemoral TAVR (TF-TAVR), which is the traditional approach performed via the groin, and transapical TAVR (TA-TAVR), which is performed via the heart muscle. TA-TAVR is an alternative for patients who are medically ineligible for TF-TAVR secondary to severe peripheral vascular disease. While the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release (and related study) looks at both TF-TAVR and TA-TAVR patients. It\u00a0notes the frequency of adverse health outcomes associated with the two procedures. For example 30-day stroke risk for TF-TAVR was 3.6 percent, and 35 percent of TF-TAVR patients had \u201cmajor complications, such as bleeding or vascular issues.\u201d Stroke risk for TA-TAVR was 2.0 percent and 32 percent of TA-TAVR patients had major complications.\nThat\u2019s useful information, but the release neglects to mention the higher mortality rate observed in the TA-TAVR group compared with TF-TAVR \u2014 a difference that was not trivial. Overall, 4.6% of patients in the TF-TAVR died within 30 days or as a complication of the procedure. Among the TA-TAVR, the rate was 13%.\nOverall, we think the lack of any mention of death rates related to the procedure unbalances the discussion of harms. We also think it\u2019s problematic that the headline of the release describes TAVR as \u201csafe,\u201d when the second half of the release makes clear that there are substantial health risks associated with the procedures. Since the patients in this study were not randomly assigned to the valve treatment or conservative care, it is difficult to know for sure how the risks compare. The release could have done more to highlight that these patients are at high risk based upon age and their valve disease, and that it isn\u2019t clear whether the complications and deaths associated with these procedures are greater than what would be expected with conservative care.", "answer": 0}, {"article": "Jefferson, through its academic and clinical entities of Thomas Jefferson University and Jefferson Health, including Abington Health and Aria Health, is reimagining health care for the greater Philadelphia region and southern New Jersey. Jefferson has 23,000 people dedicated to providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies to define the future of care. With a university and hospital that date back to 1824, today Jefferson is comprised of six colleges, nine hospitals, 34 outpatient and urgent care locations, and a multitude of physician practices throughout the region, serving more than 100,000 inpatients, 373,000 emergency patients and 2.2 million outpatients annually.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups. Women getting the faster fluid rate (250 milliliters per hour) were less likely to get a cesarean section. The higher fluid rate also reduced the overall time of labor by an average of 64 minutes, and shortened the pushing phase by nearly 3 minutes, on average.\n\"We've known that it's important for women to stay well hydrated during pregnancy and labor. This study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella. \"Recently, we also showed that letting women eat more liberally in labor, especially in early labor, has benefits including shorter labor, and no identifiable risks.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "An important potential risk of pulmonary edema (fluid build-up in the lungs) due to higher levels of intravenous hydration is not mentioned in the release, although it was reported in the article.\nAdditionally, the release neglects to explain that the only studies pooled for this analysis were those performed on low-risk, first-time mothers whose labor was not induced. The original research report notes that the effectiveness and safety of giving increased fluids to women who had given birth previously, whose labor was induced or who have other medical issues, is unclear. This is an important caveat that belongs in the news release.", "answer": 0}, {"article": "Ambivalence over the test hasn't been confined to the United States.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life. However, since the benefit of PSA screening requires at least 10 years to be borne out, it still seems questionable to test PSA for men over 70, the researchers noted.\nAmong screened men, 11.4 percent were diagnosed with prostate cancer, compared with 7.2 percent of unscreened men. Of the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although reporting that \u2018just 12 men would need to be diagnosed with prostate cancer in order to save one life\u2019 the story neglected to follow though and examine the harm done to the other 11 men. \u00a0There are psychological consequences of a cancer diagnosis. \u00a0In addition, it wasn\u2019t just that men were diagnosed with prostate cancer that affected the chance that they would die from prostate cancer \u00a0\u2013 at least some of these men also received treatment for prostate cancer. \u00a0There was no discussion of the possible harms that are a consequence of prostate cancer treatment.\nThese are not easy issues, but the story did not mention that the number needed to screen to prevent one cancer death was 293.\u00a0 Those who were screened and got a false positive, perhaps leading to unnecessary followup testing like a biopsy, experienced harms. ", "answer": 0}, {"article": "Any health care provider who is licensed to prescribe medicine can prescribe naltrexone \u2014 not just mental health professionals or addiction specialists. As as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\nNaltrexone is certainly not a cure-all, researchers say. And it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\n\"I use these medications as an adjunct to therapy, and group [sessions] and 12-step meetings\" says Dr. Jeffrey Hsu, a psychiatrist at Johns Hopkins University who is certified in addiction medicine. He says that when used alone the medicines are only modestly effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions the drug is \u201csafe,\u201d but does not discuss any side effects of the drug, nor notable interactions or contraindications. For example, this drug can\u2019t be used if the person is prescribed or otherwise taking opioids, too, or has certain types of liver damage.", "answer": 0}, {"article": "The FDA said the safety and efficacy of Yescarta were established in a multi-center trial of more than 100 adults with large B-cell lymphoma. An independent review committee found that 72 percent of patients treated with a single infusion responded to therapy, including 51 percent who then showed no evidence of remaining cancer. Kite has said that at six months, 44 percent of patients were still responding, with 39 percent having no sign of cancer.\nBiotech analysts had expected the Kite price to be lower than Kymriah's, in part because the number of eligible patients is larger and the response rates are lower. Even so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\nThe Food and Drug Administration approved a second version of a groundbreaking treatment Wednesday that genetically alters patients' cells to attack cancer \u2014 this time, to fight aggressive non-Hodgkin lymphoma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wisely documents the harms found in the trials for the drug, including patient deaths. This is important, and helps balance the glowing patient anecdote from a woman whose cancer went into remission.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 We don\u2019t know what the harms of strawberry consumption would be.", "answer": 2}, {"article": "The study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\n\"The results confirm that increasing omega-3s is a healthy lifestyle intervention that can contribute towards reductions in CHD risk,\" added Adam Ismail, Executive Director of GOED. \"Remember that increasing omega-3 intakes is basically just improving the quality of one's diet slightly, like reducing the amount of sodium or increasing your dietary fiber. It is a simple, inexpensive, and achievable change that most consumers need to make to optimize their health.\"\n\"What makes this paper unique is that it looked at the effects of EPA and DHA on coronary heart disease specifically, which is an important nuance considering coronary heart disease accounts for half of all cardiovascular deaths in the U.S.,\" said Dr. Dominik Alexander, lead author and Principal Epidemiologist for EpidStat. \"The 6 percent reduced risk among RCTs, coupled with an 18 percent risk reduction in prospective cohort studies -- which tend to include more real-life dietary scenarios over longer periods -- tell a compelling story about the importance of EPA and DHA omega-3s for cardiovascular health.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential problems associated with omega-3s. And there are potential harms. For example, the University of Maryland Medical Center notes that patients should consult with their doctors about potential interactions with prescription drugs before taking omega-3 supplements, and adds that \u201cHigh doses of omega-3 fatty acids may increase the risk of bleeding, even in people without a history of bleeding disorders, and even in those who are not taking other medications.\u201d There are concerns about other potential harms as well, such as whether fish oil supplements may increase risk for prostate cancer. We don\u2019t expect a news release to include an exhaustive summary of all the possible harms associated with a particular intervention. But we do expect a news release to at least acknowledge that the potential for harms exists, when appropriate.", "answer": 0}, {"article": "For more further information, you can see the studies here and here.\nDr. Senay said another study done in Stockholm, Sweden observed that the decline of patients with a very mild form of Alzheimer's Disease after they began taking supplements that contained two Omega-3 fatty acids.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay. \"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that there is \u201cno harm in doing the Mediterranean diet\u201d. However, people still need to maintain appropriate caloric consumption, regardless of the type of diet. Excess calories, even from healthy food, can cause weight gain. What is not discussed in the news story, but is mentioned in the source article is that greater adherence to the Mediterranean diet was associated with lower caloric intake. Also, the addition of daily moderate consumption of wine may be problematic for those who cannot drink alcohol. One to two alcoholic drinks per day has been shown to slightly increase the risk of breast cancer in women. ", "answer": 0}, {"article": "\u201cThis is great science,\u201d says J. Stephen Jones, MD, chairman of the department of regional urology at the Cleveland Clinic in Ohio.\nResearchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While alluding to problems with the PSA test, the story did not cover any potential problems that might arise with the experimental test. \u00a0Although this test may potentially improve the accuracy of a man\u2019s risk estimate, there was still a fair amount of overlap and uncertainity. \u00a0The story did not report the proportions of cancers that were low and high risk. \u00a0Finding a low risk cancer could be considered a harm because many are considered overdiagnosed. \u00a0Missing a high risk cancer also causes harm.\nThis new test was suggested to eliminate the problem that arises because \u2018it\u2019s up to the patients and their doctors to figure out what to do next\u2019 when an elevated PSA level is detected. \u00a0However \u2013 even if this new test were available \u2013 it would still be up to patients and their doctors to determine what next steps to take.", "answer": 0}, {"article": "Parents are beginning to take baby boxes home from hospitals along with their newborns. A Los Angeles-based company has partnered with health officials to give the boxes away for free and an online initiative offers advice aimed at reducing sudden unexpected infant deaths. New Jersey and Ohio were the first to participate statewide in the program.\nThe boxes are a new idea for many Americans.\nPeterson\u2019s daughter, Ariabella, just turned 3 months old. She said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any mention of harms. Just because something doesn\u2019t seem harmful, we would still like a story to note \u201cThere are no known harms\u201d because that means they\u2019ve given it some thought.", "answer": 2}, {"article": "Changing the schedule of a drug falls to the Drug Enforcement Administration or the Department of Health and Human Services. An interested party, such as a drug company, may also petition for the process to begin. The Food and Drug Administration and the National Institute of Drug Abuse provide guidance to the DEA when reviewing scientific evidence on which to base a schedule change.\nHe noted that generating more evidence of effective use is \"a good thing.\"\n\"No one study decides an issue; the sample size is still relatively small (because this is a rare syndrome and so hard to study large numbers of cases) and the duration of treatment so far has been relatively short,\" Hall, who was not involved in the research, wrote in an email.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely refers to the harms up high and then returns to them in greater detail later in the piece. It also does something we see too rarely, which is mention how many patients dropped out of the study.", "answer": 1}, {"article": "Research has shown that the brains of people with A.D.H.D. on average look and function differently than those who don\u2019t have the disorder, particularly when it comes to processing two important neurotransmitters: dopamine and norepinephrine. For most people with A.D.H.D., stimulants can temporarily boost focus, motivation and self-control by increasing the availability of these chemical messengers. The question is whether these effects can last once the drugs have left the bloodstream.\nKatherine Ellison is an author or co-author of four books about A.D.H.D. and education, including \u201cBuzz: A Year of Paying Attention.\u201d\n\u201cThere might be quite a profound neurological benefit,\u201d he said in an interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cries out for some details about the downsides of medication. It includes a statement that most children quit taking their medicine. Why? Again, the story seems to assume that readers are ADHD aficianados.", "answer": 0}, {"article": "But don't rush out to adopt a furry friend just yet.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life. In other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\nWhat's more, Kozyrskyj's study suggested that the presence of pets in the house reduced the likelihood of the transmission of vaginal GBS (group B Strep) during birth, which causes pneumonia in newborns and is prevented by giving mothers antibiotics during delivery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release release. Presumably there are some dangers of exposing babies in the womb and newborns to pet dogs and cats but we aren\u2019t given any hint that they exist or what they are. One of the most common \u201charms\u201d associated with furry pets is allergies, the very condition this study purports to lessen or prevent.", "answer": 0}, {"article": "At about 40 months after diagnosis, the women who received the surgery plus standard therapy lived an average of nine months longer than their counterparts who received standard therapy alone. Nearly 42 percent of the women who received surgery lived to five years after diagnosis, compared with less than 25 percent of the women who did not receive surgery.\nThis research was primarily funded by the Turkish Federation of Societies for Breast Diseases. The study received scientific advisement from UPMC and assistance with statistical analysis from epidemiologists at the University of Pittsburgh Graduate School of Public Health.\nThe results of the phase III randomized, controlled trial will be presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release of the risks associated with surgery. It\u2019s unclear from the abstract whether the study captured the risks involved in the surgeries.", "answer": 0}, {"article": "After the four nights of sleep deprivation, the volunteers\u2019 insulin sensitivity had fallen by 23 percent and their bodies had started to produce extra insulin. But when researchers checked again after two nights of extended rest, the men\u2019s insulin sensitivity, and the amount of insulin their bodies produced, had returned to normal, mirroring what was seen during the portion of the experiment when the volunteers consistently got a good nights\u2019 rest.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email. \u201cIdeally, we would all get sufficient sleep on a nightly basis.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hard to imagine the \u201charms\u201d of getting more sleep, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Patients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story glosses over potential harms when it unquestioningly accepts one of the researcher\u2019s claims that statins are \u201csafe, cheap, and an easy intervention in terms of delivery.\u201d Even if we accept that this is true for patients who take statins to prevent heart disease, it might not be true for patients who start taking the drug once they contract pneumonia. The story should have mentioned this, as well as the other common adverse effects of statin medication, which include muscle pain and gastrointestinal upset.", "answer": 0}, {"article": "About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.\nThe need for laser treatment varied among the three treatment groups. By two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.\nAmong participants with 20/40 or better vision at the trial\u2019s start, all three drugs improved vision similarly on an eye chart. On average, participants\u2019 vision improved from 20/40 vision to 20/25.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cThe risk of heart attack, stroke, or death from a cardiovascular condition or an unknown cause by the end of the trial was higher among patients in the Lucentis group. Twelve percent of Lucentis participants had at least one event, compared with five percent of the participants in the Eylea group and eight percent of the participants in the Avantis group.\u201d \u00a0This is useful information. The release also points out that more study is needed to determine if these treatments affect the rate of heart problems or if this observation was due to chance.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.\nPrevious studies have shown rapid antidepressant effects from sleep deprivation for roughly 40-60 percent of individuals, yet this response rate has not been analyzed to obtain a more precise percentage since 1990 despite more than 75 studies since then on the subject.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity. Also, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are many harms associated with sleep deprivation and these are not mentioned. Johns Hopkins has an info-graphic identifying some of them which include adverse effects on mood, memory and health.", "answer": 0}, {"article": "July 7, 2011 -- An experimental therapy involving stem cell injections from the patient's own blood is showing promise in the treatment of people with chest pain that is not responsive to drugs, angioplasty, or surgery. Results from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research. Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\n\nDrugs, angioplasty, and coronary artery bypass graft (CABG) surgery are the main treatments for angina -- chest pain caused by blocked coronary arteries. About 850,000 Americans have angina that persists despite available treatments. \"These are patients who have been on drugs and may have had multiple angioplasties or CABG surgeries,\" AHA President Gordon Tomaselli, MD, tells WebMD. \"Their activities are severely restricted by their chest pain and right now we have little to offer them.\" The new treatment came from the discovery about a decade ago that CD34+ stem cells stimulate the formation of new blood vessels, study researcher Douglas W. Losordo, MD, of Chicago's Northwestern University tells WebMD. \"Coronary artery disease involves not only the blockage of major arteries, but the death of small vessels, or capillaries, of the heart muscle,\" he says. \"This treatment targets these small vessels that have been damaged. The stem cells have shown the ability to repair and replace them in animal models.\" The approach also showed promise in a 2007 pilot study involving fewer than 30 patients. The newly reported study included 167 patients with severe angina treated at 26 medical centers across the country.\n\nStudy participants received one of three treatments: low-dose CD34+ injections, high-dose injections, or placebo. Patients were given a drug for several days to increase the number of CD34+ stem cells in the blood. Blood was collected and processed to collect the stem cells, and then, using a catheter threaded into the heart, the researchers injected the CD34+ cells into areas of the muscle that had been identified as oxygen-deprived areas. The patients received 10 such injections during a single catheterization procedure.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit for the following \u2013 although we think it was incomplete:\n\u201cAbout one in three patients had elevations of a cardiac enzyme that is associated with heart attacks. While the elevations did not appear to be clinically significant, Losordo says the researchers will continue to closely monitor cardiac enzymes in patients who receive the treatment.\u201d\nWhat does that mean?\u00a0 \u201cAssociated with heart attacks\u201d?\u00a0 How? Why? How often? In what past research?\u00a0 And what does \u201cdid not appear to be clinically significant\u201d mean?\u00a0 Did it cause any problems or didn\u2019t it?", "answer": 1}, {"article": "Until lately, such patients have had only one surgical option: ankle fusion surgery, in which the worn-out part of the joint is removed and the bones are permanently locked together with screws and plates. The procedure usually relieves pain, but the patient loses mobility in the ankle, leading to changes in gait and, ultimately, additional wear and tear and arthritic pain in other parts of the ankle. About 25,000 ankle fusions were performed in the United States last year.\n\u201cFor an ankle replacement you have to be a little more picky in who you select for those cases,\u201d he said. \u201cBut I can\u2019t tell you how many patients come in, and I mention this option they don\u2019t even know exists.\u201d (Dr. Radnay, who says he has performed more than 100 ankle replacements using an Inbone device from Wright Medical Group of Arlington, Tenn., is now a paid consultant to the company, helping to gather data on long-term success rates.)\nHis surgeon, Dr. Craig S. Radnay, an associate at the Insall Scott Kelly Institute for Orthopedics and Sports Medicine in New York City and on Long Island, says he is now a \u201cbig believer\u201d in ankle replacement for certain patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presents some risks, i.e. replacement failure, loosening, slow healing, infection\u00a0and amputation.\u00a0 It\u00a0also mentions that not all individuals are appropriate candidates for surgery.\u00a0 It could have provided numbers for how often these harms occur.\u00a0 Nonetheless. we\u2019ll give it the benefit of the doubt on this criterion and grade it barely satisfactory. ", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the potential harms of Brilinta. \nGiven the questions about risks of the reigning anti-platelet blockbuster Plavix it intends to replace, this is a significant omission.\nThe risks linked to Plavix could therefore arguably demonstrate a need for a drug that reduces heart risk without introducing other potential harms. \nThis should have been mentioned, as should have any potential risks early data link to Brilinta.", "answer": 0}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not alert readers to the serious risks of immunotherapy for cancer. The drug label begins with this alert: \u201cKEYTRUDA can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.\u201d\nThe story also quotes a researcher gushing about the potential benefits of pembrolizumab, but does not report that this same researcher recently reported the case of a patient who suffered a severe case of scleroderma while taking the drug.\nNot covering the downsides of immunotherapy is something we see a lot\u2013for tips on how to write more accurately about this, see:\u00a0Too many stories ignore or under-report the harms of cancer immunotherapies. Here\u2019s what the public needs to know.", "answer": 0}, {"article": "The Society of NeuroInterventional Surgery (SNIS) is a scientific and educational association dedicated to advancing the specialty of neurointerventional surgery through research, standard-setting, and education and advocacy to provide the highest quality of patient care in diagnosing and treating diseases of the brain, spine, head, and neck. Visit http://www. and follow us on Twitter (@SNISinfo) and Facebook (@SNISOnline).\n\"By using this technology in the angiosuite, hospitals can reduce intra-facility transfer delays and hence the time of stroke symptom onset to treatment, which will significantly reduce brain damage and improve outcomes for patients,\" said Nicole Cancelliere, lead author of the study and an interventional clinical research technologist at Toronto Western Hospital.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans. The imaging allows accurate detection of hemorrhage, occlusion site, ischemic core, and tissue at risk, suggesting that baseline imaging can be performed in the angiosuite using cone beam imaging. The lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there potential risks associated with using the new software? The release doesn\u2019t say one way or the other. As noted previously, the study involved adding the new technology to standard care. So it may have actually harmed study patients. More broadly, the study was not designed to assess the relative benefits/harms of this new technique compared to the current standard.", "answer": 0}, {"article": "Scientists are inching closer to a drug that may protect peanut allergy sufferers from potentially life-threatening complications that can occur due to accidental consumption. While the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert. \u201cOn average, the participants were able to tolerate a 100-fold higher dose of peanut at the end of the study than they did at the beginning. In addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies. The study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms \u2014 and harms were significant. The CNN story reported that 11% of participants dropped out of the study as a result of untoward effects of treatment, and other participants (who completed the study) had allergic reactions requiring treatment.\nIt also left out important issues such as the high dropout rate among those who received the treatment, and unknown long-term effects.", "answer": 0}, {"article": "Alzheimer's disease is a progressive, irreversible brain disorder that destroys memory and thinking skills. The disease affects 5.5 million Americans, according to the National Institutes of Health (NIH).\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\n\"Right now it's hard to say whether an older person with normal cognition or mild cognitive impairment is likely to develop dementia,\" said lead author Cyrus A. Raji, MD, PhD, an assistant professor of radiology at Washington University's Mallinckrodt Institute of Radiology. \"We showed that a single MRI scan can predict dementia on average 2.6 years before memory loss is clinically detectable, which could help doctors advise and care for their patients.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not delve into potential harms, including anxiety and false results. If a test is accurate 95% of the time, five out of 100 people will get either a false positive, which can lead to more tests and anxiety, or a false negative, which can be wrongly reassuring.", "answer": 0}, {"article": "After three months, 16 percent of the women who were enrolled in both Text4baby and Quit4baby had quit compared with just 11 percent of women getting just Text4baby. However, the difference between the two groups did not reach statistical significance, the authors say.\n*The headline of this release was edited for clarity to match the content in the body of the release.\nThe research was supported by the National Institute on Drug Abuse, part of the National Institutes of Health. Dr. Abroms has stock in Wellpass Inc. (formerly Voxiva, Inc.) and has licensed Text2quit and Quit4baby to Wellpass.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms but it\u2019s hard to imagine there are any harms from voluntarily receiving from 1 to 8 text messages a day. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "In people with osteoarthritis, the cartilage in a joint wears away in some areas. The function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\" The wearing away of cartilage leads to pain and other symptoms.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C. He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that strontium can increase the risk for deep vein thrombosis, but doesn\u2019t indicate whether the drug was associated with any adverse effects in the study.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Doctors can use a patient\u2019s abdominal CT scans to also check for signs of the bone-weakening disease osteoporosis, according to a new study.\nThe idea, say the researchers, is doctors can use patients\u2019 CT scans that are ordered for another reason - such as looking for tumors - to also check for signs of osteoporosis. That may spare the patients from additional testing and additional costs.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that both DXA and CT scans involve radiation, although it would have been helpful to note that the radiation exposure is much higher with CT scans.\nMore importantly, it addressed the risk of \u201cincidentaloporosis\u201d \u2013 or incorrect osteoporosis diagnoses that arise when doctors are looking for something else.\u00a0 We wish, though, that the story had added a line to drive home the point of the potential harm from such overdiagnosis.\n\u00a0", "answer": 1}, {"article": "The increased risks, while double in relative terms, are small. The Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story is a potential harm of treatment, namely, an increased risk of suicidal thoughts or behaviors. The story notes the risks are greater for epileptics than for those taking\u00a0 the same medications for psychiatric conditions or for chronic pain. The story does not note other, less serious harms of these drugs, which can include weight gain, mental confusion and an upset stomach. Discussion of other side effects would be useful information if patients are considering the full risks and benefits of taking this class of medication over the long-term. ", "answer": 1}, {"article": "Dr Timothy Hardy is a hepatology registrar within Newcastle Hospitals and a Medical Research Council-funded clinical research training fellow at the University. He conducted the research as part of his PhD project and said: \"We are now working on confirming these findings in a larger group of patients.\n\"Routine blood tests can't detect scarring of the liver and even more advanced non-invasive tests can really only detect scarring at a late stage when it is nearing cirrhosis. We currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of potential harms. How accurate is the new blood test? Is there a risk of false positives or misdiagnosis \u2014 and, if so, how high is that risk? The investigators assembled only a small number of carefully selected patients. Many were excluded if they had other liver diseases as well as complications from alcohol. And\u00a0the as-yet undetermined potential for both false positive and false negative results could certainly undermine its value in reassuring patients.", "answer": 0}, {"article": "CT (computed tomography), sometimes called CAT (computed axial tomography), is performed by computerized machines that scan patients with X-rays to create three-dimensional cross-sectional images of organs and other parts of the body, providing far greater detail than standard single X-rays.\nAlthough the companies that make the CT machines have been developing new protocols designed to minimize radiation exposure, particularly for children, everyone agrees that the most prudent thing to do is to eliminate unnecessary use.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger. But researchers have estimated the risk based on what is considered the best information available about the health effects of radiation -- data collected from survivors of the atomic bombings of Hiroshima and Nagasaki, as well as exposure of nuclear plant and medical workers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harms of radiation exposure due to CT scans. Notably, the story comments on how many excess cases of cancer could be explained by the radiation exposure and that some of the risk is easily avoidable: some scans are unnecessary.", "answer": 1}, {"article": "Oppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n\u201cWe went in for the assessment and her behaviors at the assessment were really terrible,\u201d Amy said. \u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms.", "answer": 0}, {"article": "Although the effectiveness of the drugs were similar, the study showed the side effects of linagliptin were much less severe than those of glimepiride. The researchers found that 7 percent of patients on linagliptin experienced hypoglycemia, compared to 38 percent of patients treated with glimepiride.\nThe study was published online June 27 in The Lancet.\nResearchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was inadequate/incomplete quantification of the harms.", "answer": 1}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nThe risk of treatment failure was 34 percent in the five-day group and 16 percent in the 10-day group. What's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were no differences in the rate of antibiotic resistance, diaper rash or diarrhea. This is just enough information to rate satisfactory\u2013but barely.\nBut unfortunately we know those markers would likely be higher in a cohort of kids taking antibiotics, versus those taking nothing (placebo). \u00a0Without a placebo arm in this trial, we have no idea what the rate of adverse effects would have likely been. A stronger story would have pointed this out.", "answer": 1}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said. \"If the fish improves sleep, great. If it also improves cognitive performance -- like we've seen here -- even better. It's a double hit.\"\nGiven the young age of this study group, Liu and colleagues chose not to analyze the details participants reported about the types of fish consumed, though they plan to do so for work on an older cohort in the future. The researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\n\"Introducing the taste early makes it more palatable,\" Pinto-Martin said. \"It really has to be a concerted effort, especially in a culture where fish is not as commonly served or smelled. Children are sensitive to smell. If they're not used to it, they may shy away from it.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Current dietary recommendations include warnings about some commonly eaten types of fish that are high in mercury, but this or any other potential drawbacks associated with consuming fish were not mentioned.", "answer": 0}, {"article": "The procedure involves collecting several ounces of blood from a patient\u2019s arm, spinning the blood in a centrifuge to concentrate the platelets and injecting the concentrated platelets into the injury site to stimulate healing. Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThe researchers call the results \u201cclinically relevant,\u2019\u2019 despite the study\u2019s small size, and say the next step should be a larger, controlled clinical trial. \u201cI\u2019ve heard some skeptics call PRP a cure looking for a disease, but it is being used in so many areas of medicine now with promising outcomes,\u201d says Marni Wesner, a sports medicine physician at the clinic and one of the study\u2019s authors. \u201cThe potential for benefit from PRP is real.\u2019\u2019\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of potential harms in the story comes in this statement:\u00a0 \u201cThe American Academy of Orthopedic Surgeons \u2014 which says PRP \u2018holds great promise\u2019 \u2014 describes the risk as minimal.\u201d\u00a0 That\u2019s not\u00a0acceptable given that there is no explanation of what those risks might be. Readers are\u00a0left\u00a0clueless when it comes to questions of potential harms.", "answer": 0}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Use of Avodart\u00a0is associated with increased risk of sexual side effects and a small increase in heart failure risk. The story didn\u2019t mention these potential problems.", "answer": 0}, {"article": "The study used samples from patients in both Denmark and the US, at different stages of the disease.\nIn the future, the screening method could be used to screen people who are at a higher risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients and patients with chronic inflammation of the pancreas.\nDue to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression. Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer. By 2030, pancreatic cancer is expected to be the second deadliest type of cancer in the world.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed and two types of harms are relevant here. The study \u2014 but not the news release \u2014 mentions a false-positive rate of 6%; that\u2019s the fraction of people erroneously diagnosed with a cancer they don\u2019t have. (Who might then go on to endure the costs and risks involved with subsequent evaluation.)\nThe flip side would be: what\u2019s the false-negative rate? That\u2019s the number of people who are told they\u2019re cancer-free but really aren\u2019t. The potential emotional harm in this case is quite clear.\nThis is important as well because pancreatic cancer is a rare condition. We know that a good screening test works best when the disease has high prevalence in a population, so when dealing with something rare, the 6% leading to harms may mean something very different.", "answer": 0}, {"article": "\"He was getting into fights. He wasn't doing his homework. He was being very difficult with his little brother. And he was just melting down day after day,\" Ellison says. \"So I decided to devote a year to trying out different approaches to see if we could make it any better.\"\nA team at The Ohio State University has nearly completed a pilot study of neurofeedback for ADHD that was funded by the National Institute of Mental Health.\nEven though there are studies now showing that neurofeedback works for ADHD, all of these studies have serious limitations, researchers say. So the approach remains promising but unproved, says David Rabiner, a researcher at Duke University who writes a newsletter about treatments for ADHD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to discuss\u00a0any potential harms of neurofeedback treatment.\u00a0The most prominent of these is\u00a0that patients\u00a0could forego other treatment approaches that have better supporting evidence and are more likely to reduce symptoms.\u00a0There is also some evidence that\u00a0neurofeedback can cause seizures or make\u00a0symptoms\u00a0worse in some individuals with psychological disorders.\u00a0In addition, the need for frequent treatments may necessitate taking a child out of school.", "answer": 0}, {"article": "Adults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the benefit of the doubt here because the story does mention the possibility of unintended harms from brown fat-activating treatments. However, we thought it was worth noting \u2014 as the authors of the study did in their paper \u2014 that the hormones that activated brown fat in this study are elevated during heart failure and cancer-related wasting. Thus, any weight loss they produce may be accompanied by important adverse effects.", "answer": 1}, {"article": "\"It seems perhaps they are on a slightly different developmental trajectory,\" Bosl said.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\nEEGs are also relatively inexpensive, painless and safe, Bosl said. And unlike MRIs, they require no sedation, so testing could be put to widespread use, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were quantified. Instead, readers were told that the EEG is \u201cpainless and safe.\u201d The story presses the idea that \u201cearly intervention is extremely important\u201d even though the study did not detect autism in any way that would warrant treatment. What would be the next step for these children? Should they be put into behavioral therapy, put on a restrictive diet, given drugs of some kind? All of these options have potential consequences that could, indeed, prove harmful to the children, especially if they are falsely diagnosed as having autism. And, like most screening tests, there is the additional potential harm of unnecessary worry for some parents, as it is likely that at least some kids will \u2018screen positive\u2019 and then develop normally.\nScreening tests have harms.\u00a0 It is a common journalistic pitfall to overlook this fact.", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because of the lack of evidence, it is difficult to quantify the harms. But the story did a nice job of addressing the harms. \"Some side effects have been reported. Because the device uses large electrical bursts, it can trigger fast heartbeats. Four such cases out of about three dozen patients were described in a recent report by Ken Thomson, a radiologist in Melbourne, Australia. AngioDynamics says that these cases have all been treatable and that the company has taken technical steps to minimize such future occurrences. One case reported to the FDA was of a U.S. patient who in July suffered a serious hemothorax, or blood buildup between the chest wall and lungs. The patient had to stay in the hospital for 16 days, and doctors said an artery \"most likely\" was punctured during the operation. AngioDynamics said in the FDA report that such a puncture is a \"possible complication\" of any such operation.\" This is more detail than is provided in most stories, even when there is much more evidence available.", "answer": 1}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nThroughout a 52-week study period, a total of 315 hypogonadal men were randomized either to LPCN 1021 or T gel (active control). Of the 315 men, 210 were randomized to LPCN 1021 and 105 were randomized to active control. Following a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks. They returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does describe adverse effects reported in the study, including that there were no \u201chepatic, cardiac or drug-related serious adverse events.\u201d It lists the percentages of patients in each of the treatment groups who had certain adverse effects, and notes that lipid levels were comparable in the two groups and androgenic measurements showed no significant differences during the study period. However, the news release fails to acknowledge long-term safety concerns, including the FDA\u2019s call last year for manufacturers to conduct a controlled clinical trial to clarify how testosterone might affect cardiac health. The abstract presented at the medical conference (the only available information about the study) states that the total numbers of adverse events was almost the same in both groups (67% in oral group compared with 65% in the topical group) without specifying the statistical significance of that result or the types of adverse effect in these groups. \u00a0The adverse events given only add up to about 10% in both groups.", "answer": 0}, {"article": "Individuals who ate between 10 a.m. and 6 p.m. consumed around 350 fewer calories, resulting in a loss of 3 percent body weight, and their blood pressure dropped by around 7mm Hg. However, their fat mass, insulin resistance and cholesterol levels were similar to the control group's.\nFurther research is now needed to uncover whether 16:8 works better than other fasting diets in terms of weight loss and health benefits.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fasting for brief periods is pretty safe, although the story could have mentioned risks of dehydration, sleep problems, or headaches that might come from getting too hungry.", "answer": 1}, {"article": "Does it cross her mind what would have happened if she didn't have the ultrasound?\nRight now the American Cancer society recommends an MRI in addition to a mammogram for women who are at high risk for breast cancer. But this study - the most definitive so far - may encourage more doctors to consider ultrasound, which is easier and less expensive.\nIn today's study of about 2,809 women with dense tissue and other risk factors, mammography alone found only half of the cancers. Mammography with ultrasound spotted 78 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the potential harms of treatment, which may be an increase in false-positives,\u00a0unnecessary biopsy, and anxiety.\u00a0 False positives may decrease with additional screening, such as an MRI, or when ultrasound is done annually.\u00a0 The high rate of false positives with mammography plus ultrasound meant that only about 1 in 10 women with cancer suspected on combined screening turned out to have cancer when biopsy was done,\u00a0whereas about 1 in 5 women with abnormal mammograms alone actually had cancer. ", "answer": 1}, {"article": "Funders of this research include that National Institutes of Health and the University of Texas System. The experiment was designed, analyzed and written up with coauthors Alessia Lodi, John DiGiovanni and Achinto Saha, all of UT Austin. Additional authors include Xiyuan Lu, Bo Wang, Enrique Sentandreu, Meghan Collins, all of UT Austin; and Mikhail Kolonin of The Brown Foundation Institute of Molecular Medicine at the University of Texas Health Science Center in Houston.\nDuring the past decade, some cancer research has highlighted the potential therapies found in plants, including chemicals found in foods such as turmeric, apple peels and green tea. These compounds minimize one of the risk factors for cancer, inflammation within the body. People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Plant chemicals are generally considered safe, but there\u2019s potential for toxicity if they\u2019re consumed in combination with certain drugs or at high concentrations. There\u2019s added risk for consumers who buy these substances in the form of dietary supplements, which are not tightly regulated by the FDA.", "answer": 0}, {"article": "The new study focused on 395 pairs of melanoma survivors who had received training in skin exams in the original study. The participants attended \u201cbooster\u201d training sessions and completed surveys every four months for the next two years.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nFor now, she said people can go to the American Academy of Dermatology's website to learn the steps - known as the ABCDEs - of finding melanoma (bit.ly/2h9zl0Y).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Having a partner check for melanomas doesn\u2019t have immediate harms, so we\u2019ll rate this N/A. It could be harmful if a person relies too heavily on a friend\u2019s assessment versus a physician\u2019s though.", "answer": 2}, {"article": "Women who underwent screening reduced their risk of dying from breast cancer by 49 percent. Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent. The risk reduction in younger women, aged 50 to 69, was smaller, at 39 percent, but still considered substantial.\nThe routine screening also lowered the chances of being diagnosed with an advanced cancer, she said.\nThe study findings ''add to the body of evidence supporting the fact that mammography matters in improving detection and survival,\" said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City. \"This study focuses on survival.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article refers briefly to \u201covertreatment\u201d but fails to explain this or other potential harms.", "answer": 0}, {"article": "A vocal subset of parents and activists blame vaccines, especially those with the mercury-based preservative thimerosal, which has been banned from virtually all as a precaution. Numerous studies have found no connection between autism and vaccines or thimerosal.\n\"These people are preying on the fears of parents. We cannot be using these children who are so vulnerable as guinea pigs in a medical experiment.\"\n\"The kids don't understand. They have impulses. It's what happens when you have high testosterone,\" Badillo said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job dedicating quite a bit of discussion to potential harms from this approach \u2013 both known and unknown. ", "answer": 1}, {"article": "\"It's certainly not a breakthrough,\" he said.\nDeep brain stimulation also is expensive. At Froedtert Hospital the procedure costs about $120,000, an amount that generally is covered by Medicare and private insurance.\nThe problem with deep brain stimulation is that many doctors are not aware of its benefits or don't know how to determine the appropriate patients based on risks vs. potential benefits, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the \"much greater risk of serious adverse side effects\" in the same sentence that delivers the positive results. Placing the \"bad news\" of side effects right alongside the \"good news\" of improvements is a best practice for which this reporter should be commended.\nLater in the story the reporter lists these side effects and provides data on the number, severity and duration of the side effects. The story also mentions the death that resulted from the surgery.\u00a0\nYet the story fails to mention that the study found consistent, if small, loss of cognitive function in the stimulation group. It also fails to mention that the long-term effect of the sugery is unknown, and that this study, lasting just six months, cannot help answer that question.\u00a0 ", "answer": 1}, {"article": "The blood test found lymphoma and myeloma with slightly less accuracy, at 77% and 73%, and bowel cancer in two out of three patients. Lung cancer was detected in 59% of patients. Head and neck cancer was detected in 56% of patients.\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\nA blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no mention of what many experts consider to be the most important considerations when it comes balancing the harms vs. benefits of liquid biopsies. These include:", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The minimally invasive surgery seems safer than other kinds of surgery, but without any specific details on the potential for harms, we can\u2019t be sure. We are told that most patients experienced more frequent urination after the procedure, but that the improvements\u00a0may take four weeks or so to be seen.", "answer": 0}, {"article": "At one year, 5 percent of the study participants taking omega-3s had developed a psychotic disorder (2 of 41 people), compared to 28 percent of those on placebo (11 of 40). People taking fish oil also showed significant reductions in their psychotic symptoms and improvements in function, while they were at no greater risk of adverse effects than people taking placebo capsules.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nTrials of medications for treating mental illness typically don\u2019t include people younger than 18, Amminger noted, while starting minors on these medications is \u201calways very difficult, and always quite controversial.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While fish oil supplements are generally recognized as safe, the story could have told readers about potential side effects which can be gastrointestinal and include blood clotting problems, particularly for people taking blood thinners.\u00a0 ", "answer": 1}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers. The shot turned off a newly identified cholesterol regulator, PCSK9, which interferes with the liver's ability to clear bad cholesterol from the bloodstream.\nDr. Dan Rader, director of preventive cardiology at the University of Pennsylvania, said that PCSK9 is \"the hottest target for new treatments to lower LDL cholesterol.\" And these study results will probably fuel that fire, he added.\nMONDAY, Nov. 14, 2011 (HealthDay News) -- Preliminary research suggests that a single injection of a man-made protein might lower levels of \"bad\" cholesterol.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that researchers reported\u00a0no \u201cserious\u201d side effects with the drug. OK, but\u00a0\u00a0we wish the story had mentioned that this study was really much too small\u00a0to even estimate adverse effects. In the past, other monoclonal antibodies\u00a0have produced rare but serious adverse effects- something that could have provided meaningful context for readers.", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addressed the major concern with these medications: that it \u201cremains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.\u201d\nThe story story also reported the new drugs have \u201ca lower side-effect profile\u201d than other medications commonly used for migraine, and mild constipation was the most serious side effect of the drugs in the trials.\nThe story could have mentioned other adverse events. For example, with Emgality, hypersensitivity reactions such as rashes were reported in clinical studies.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are not broached here. This is an issue for a topic such as this, as one could imagine readers expressing concern about the efficacy of a non-human \u201ctherapist.\u201d The story actually acknowledges that concern in its second paragraph (\u201cIt [the use of technology] might seem surprising, since therapy, more than many other kinds of medicine, is so focused on the relationship between patient and therapist.\u201d But it never digs into the possible debits of wrestling with moderate depression online. We also think the story should have discussed the risk patients being victimized in an open source or relatively open chat room or other online group setting. One important element of psychiatry is privacy and patient confidentiality.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues. Osteoarthritis, which is usually felt only in the joints, is caused by wear and tear on the body.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011. The studies included arthritis patients aged 18 or older who had hip or knee replacements.\nWEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of joint replacement are the focus of the story, but there is no attempt to put them in perspective for readers.\nThe story does not tell readers how high or low the rates of complications are. It says people with rheumatoid arthritis had higher rates of dislocation and infection after a joint replacement than those with osteoarthritis, but no relative or absolute risk statistics are reported. The story pulls a quote from a news release saying \u201ccomplication rates are low,\u201d but \u201clow\u201d is not defined.", "answer": 0}, {"article": "\u2022 Less development of fatty liver,\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\nNewswise \u2014 Bethesda, Md. (March 23, 2017)\u2014Statin drugs are widely used to manage high cholesterol and reduce the risk of cardiovascular disease. But in a new review of more than 50 studies, researchers cite reductions in liver inflammation and improvements in other related factors as reasons why statins make good candidates for treating chronic liver disease. The article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers acknowledge that statin drugs can contribute to liver damage in some people, but the statement that \u201cstatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk,\u201d doesn\u2019t seem to adequately address the potential harms.\nPeople who are prescribed statins must undergo liver function tests since this class of drugs can cause rare but serious liver dysfunction. Deciding to give someone with advanced liver disease a statin as a means to help the patient\u2019s liver is unproven and has the potential for real harm.\nWe aren\u2019t provided any context on how significant the damage can be to those with advanced liver disease, or even in otherwise healthy people.", "answer": 0}, {"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the study, 9 out of 99 (9%) of patients in the sham group reported at least one adverse event compared to 14 out of 102 (14%) in the sTMS group. Even though the authors suggest the adverse events were similar between the groups, the story should have reported this.\u00a0 Furthermore, we have no long-term information about problems associated with magnetic pulses in the brain, nor do we know about long-term effects on the primary endpoint, namely headache. Could they worsen over time? ", "answer": 0}, {"article": "Heart scan law could lead to 1,000s more cancer cases\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe legislation was introduced in 2007 and passed quietly this year. It eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate. The scans are sometimes criticized as an example of expensive new technologies being adopted before proof is established that they're better than cheaper existing methods \u2014 an issue at the heart of the health care reform debate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n \nThe potential cancer risk caused by CT screening for signs of heart disease is the point of this story. Also, by highlighting uncertainty about the benefits of the screening and recapping debate over the Texas law mandating coverage of the scans, the story emphasizes the importance of considering potential harms when setting public policy on screening tests. A longer story could have considered other potential harms, including the side effects of treatments prescribed based on screening tests.", "answer": 1}, {"article": "The BRCA1 and BRCA2 gene mutations put women at high risk for breast, ovarian and other cancers, but mutations of other genes are believed to confer extra risk as well.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\n\u201cThere\u2019s a lot of controversy even among experts,\u201d said the senior author of the new study, Dr. Leif W. Ellisen of Massachusetts General Hospital Cancer Center in Boston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms, including having uncertain results leading to psychological difficulties, were mentioned in a quote from the lead author, who also discussed the complexity of interpreting the results. The article also quoted him as saying that misinterpretation could potentially lead to \u201ca drastic, unnecessary surgical procedure\u201d.", "answer": 1}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\"Our study did not address whether racial/ethnic differences in breastfeeding contribute to disparities in stroke risk. Additional research should consider the degree to which breastfeeding might alter racial/ethnic differences in stroke risk,\" Jacobson said.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Breastfeeding may be \u201cnatural,\u201d but it\u2019s not effortless. Breastfeeding can be time-consuming and exhausting, and carries risks of dehydration and breast pain. That said, these are not necessarily medical issues that rise to the level of discussion in a news release about an observational study like this one. As such, we\u2019ll rate this criterion as not applicable.", "answer": 2}, {"article": "The female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\nYou've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a good discussion of the drawbacks of condom use, for both male and female condoms.", "answer": 1}, {"article": "Roots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication. The first group engaged in yoga and mindfulness-based stress reduction (MBSR), which focuses on being aware of and accepting physical discomfort. The second group participated in cognitive behavior therapy (CBT) to change pain-related thoughts and behaviors during eight weekly two-hour group sessions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \u2018adverse event,\u2019 most often an increase in pain due to yoga.\u201d It\u2019s good to see that included. Since the story is effectively comparing MBSR to CBT and conventional treatment, it would also have been worth noting \u201cadverse events\u201d for those groups in the study. According to the study, 10 percent of the CBT group also experienced \u201cadverse events,\u201d and no adverse events were mentioned for the control group.\nDefining \u201cadverse events\u201d would also have been good, since it\u2019s not clear whether they mean momentary pain or a debilitating flare-up of long-term pain. According to the study, the pain\u2013for both MBSR and CBT groups\u2013was \u201cmostly temporary\u201d and no \u201cserious\u201d adverse events were reported. Those things are worth mentioning. (It\u2019s also worth finding out what \u201cmostly\u201d and \u201cserious\u201d mean.)", "answer": 1}]